Predictive Oncology (POAI) 10-Q 8 Aug 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 04, 2014
Document Information [Line Items]	'	'
Entity Registrant Name	'Skyline Medical Inc.	'
Entity Central Index Key	'0001446159	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'SKLN	'
Entity Common Stock, Shares Outstanding	'	222,975,766
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash	$40,151	$101,953
Accounts Receivable	149,640	97,245
Inventories	360,663	122,175
Prepaid Expense and other assets	149,524	60,588
Total Current Assets	699,977	381,961
Fixed Assets, net	204,658	158,110
Intangibles, net	68,137	53,355
Total Assets	972,772	593,426
Current Liabilities:	'	'
Accounts payable	1,625,330	1,062,108
Accrued expenses	2,194,486	2,057,957
Short-term note payable net of discounts of $46,072 and $0 (See Note 8)	81,124	280,000
Deferred Revenue	5,000	69,000
Total Current Liabilities	3,905,940	3,469,065
Accrued Expenses	290,344	331,216
Liability for equity-linked financial instruments (See Note 9)	130	11,599
Total Liabilities	4,196,414	3,811,880
Commitments and Contingencies	0	0
Stockholders' Deficit:	'	'
Common stock, $.01 par value, 800,000,000 authorized, 222,869,997 and 219,937,619 outstanding	2,228,700	2,199,376
Additional paid-in capital	26,647,135	23,279,585
Deficit accumulated during development stage	-32,099,683	-28,697,415
Total Stockholders' Deficit	-3,223,642	-3,218,454
Total Liabilities and Stockholders’ Deficit	972,772	593,426
Series A Convertible Preferred Stock [Member]	'	'
Stockholders' Deficit:	'	'
Series A Convertible Preferred Stock, $01 par value, $100 Stated Value, 40,000 authorized, 20,550 outstanding	$206	$0

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS [Parenthetical] (USD $)	Jun. 30, 2014	Dec. 31, 2013
Discount on short term note payable (in dollars)	$46,072	$0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	800,000,000	800,000,000
Common stock, shares outstanding	222,869,997	219,937,619
Series A Convertible Preferred Stock [Member]	'	'
Preferred stock, par value (in dollars per share)	0.01	'
Preferred stock, stated value (in dollars per share)	$100	'
Preferred stock, shares authorized	40,000	'
Preferred stock, shares outstanding	20,550	'

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Mar. 31, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenue	$318,293	$150,856	$388,513	$278,583
Cost of goods sold	98,365	67,335	129,448	108,939
Gross Margin	219,928	83,521	259,065	169,644
General and administrative expense	1,330,222	888,133	2,509,504	2,711,216
Operations expense	291,584	204,928	556,859	409,395
Sales and marketing expense	319,303	108,593	524,223	195,562
Interest expense	14,773	126,654	32,897	222,206
Loss (gain) on valuation of equity-linked financial instruments	0	-69,251	-11,468	-88,673
Total expense	1,955,882	1,259,057	3,612,014	3,446,705
Net income (loss) available to common shareholders	($1,735,954)	($1,175,535)	($3,352,949)	($3,277,061)
Loss per common share basic and diluted (in dollars per share)	($0.01)	($0.01)	($0.02)	($0.03)
Weighted average shares used in computation, basic and diluted (in shares)	222,620,910	121,267,500	221,922,352	111,045,552

STATEMENT_OF_STOCKHOLDERS_DEFI

STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance at Dec. 31, 2012	($3,303,203)	'	$1,042,473	$14,945,435	($19,291,111)
Balance (in shares) at Dec. 31, 2012	'	'	104,247,228	'	'
Value of equity instruments issued with debt	392,556	'	'	392,556	'
Shares issued to debtors as compensation at $.15 per share	43,521	'	2,901	40,620	'
Shares issued to debtors as compensation at $.15 per share (in shares)	'	'	290,143	'	'
Shares issued under PPM to five investors at $.07 per share	500,000	'	71,429	428,571	'
Shares issued under PPM to five investors at $.07 per share (in shares)	'	'	7,142,857	'	'
Shares issued to an escrow account underlying a debt agreement	10,000	'	10,000	'	'
Shares issued to an escrow account underlying a debt agreement (in shares)	'	'	1,000,000	'	'
Shares issued to debtors as compensation at $.15 per share	34,550	'	2,303	32,247	'
Shares issued to debtors as compensation at $.15 per share (in shares)	'	'	230,332	'	'
Shares issued to an institutional investor at $.07 per share	500,000	'	71,429	428,571	'
Shares issued to an institutional investor at $.07 per share (in shares)	'	'	7,142,858	'	'
Value of shares per an agreement with a former officer	40,480	'	'	40,480	'
Shares issued to consultant as compensation at $.067 per share	16,750	'	2,500	14,250	'
Shares issued to consultant as compensation at $.067 per share (in shares)	'	'	250,000	'	'
Shares issued to former consultant exercising options at $.01 per share	2,000	'	2,000	'	'
Shares issued to former consultant exercising options at $.01 per share (in shares)	'	'	200,000	'	'
Shares issued to former CEO exercising options at $.01 per share	3,333	'	3,333	'	'
Shares issued to former CEO exercising options at $.01 per share (in shares)	'	'	333,330	'	'
Shares issued upon conversion of four notes payable at $.15 per share	156,243	'	10,416	145,827	'
Shares issued upon conversion of four notes payable at $.15 per share (in shares)	'	'	1,041,622	'	'
Shares issued for interest to the four notes payable at $.15 per share	11,170	'	745	10,425	'
Shares issued for interest to the four notes payable at $.15 per share (in shares)	'	'	74,462	'	'
Shares issued for cashless exercise of warrants at $.12 per share	2,778	'	2,778	'	'
Shares issued for cashless exercise of warrants at $.12 per share (in shares)	'	'	277,778	'	'
Shares issued for cashless exercise of warrants at $.16 per share	1,633	'	1,633	'	'
Shares issued for cashless exercise of warrants at $.16 per share (in shares)	'	'	163,334	'	'
Shares issued for cashless exercise of warrants at $.15 per share	6,327	'	6,327	'	'
Shares issued for cashless exercise of warrants at $.15 per share (in shares)	'	'	632,708	'	'
Shares issued for cashless exercise of warrants at $.20 per share	2,618	'	2,618	'	'
Shares issued for cashless exercise of warrants at $.20 per share (in shares)	'	'	261,848	'	'
Shares issued to 24 warrant holders exercised at a reduced price for $.10 per share	1,044,490	'	104,449	940,041	'
Shares issued to 24 warrant holders exercised at a reduced price for $.10 per share (in shares)	'	'	10,444,898	'	'
Shares issued to 4 PPM investors converting notes at $.12 per share	316,504	'	26,375	290,129	'
Shares issued to 4 PPM investors converting notes at $.12 per share (in shares)	'	'	2,637,534	'	'
Shares issued to 10 PPM investors converting notes at $.18 per share	1,020,200	'	54,054	966,146	'
Shares issued to 10 PPM investors converting notes at $.18 per share (in shares)	'	'	5,405,431	'	'
Shares issued to consultant as compensation at $.38 per share	57,000	'	1,500	55,500	'
Shares issued to consultant as compensation at $.38 per share (in shares)	'	'	150,000	'	'
Shares issued for two note conversions at $.014 per share	994,928	'	710,663	284,265	'
Shares issued for two note conversions at $.014 per share (in shares)	'	'	71,066,331	'	'
Shares issued for warrant exercise at $.15 per share	160,715	'	10,715	150,000	'
Shares issued for warrant exercise at $.15 per share (in shares)	'	'	1,071,429	'	'
Shares issued to an investor for a cashless exercise of warrants at $.17 per share	2,044	'	2,044	'	'
Shares issued to an investor for a cashless exercise of warrants at $.17 per share (in shares)	'	'	204,306	'	'
Shares issued to former Board Directors as compensation at $.325 per share	100,000	'	1,000	99,000	'
Shares issued to former Board Directors as compensation at $.325 per share (in shares)	'	'	100,000	'	'
Reduced warrant exercise compensation expense	2,140,946	'	'	2,140,946	'
Options issued as part of employee bonus	147,500	'	'	147,500	'
Shares issued to one investor for cashless warrant exercised at $.12 per share	2,778	'	2,778	'	'
Shares issued to one investor for cashless warrant exercised at $.12 per share (in shares)	'	'	277,778	'	'
Shares issued for a cashless exercise of warrants at $.10 per share	30,244	'	30,244	'	'
Shares issued for a cashless exercise of warrants at $.10 per share (in shares)	'	'	3,024,390	'	'
Shares issued for a cashless exercise of warrants at $.075 per share	5,447	'	5,447	'	'
Shares issued for a cashless exercise of warrants at $.075 per share (in shares)	'	'	544,714	'	'
Shares issued for cashless warrant exercise at $.13 per share	1,597	'	1,597	'	'
Shares issued for cashless warrant exercise at $.13 per share (in shares)	'	'	159,722	'	'
Shares issued for interest on two note conversions at $.18 per share	7,365	'	409	6,956	'
Shares issued for interest on two note conversions at $.18 per share (in shares)	'	'	40,918	'	'
Shares issued in settlement with a former noteholder at $.27 per share	102,060	'	3,780	98,280	'
Shares issued in settlement with a former noteholder at $.27 per share (in shares)	'	'	378,000	'	'
Shares issued for a stock option exercise at $.065 per share	650	'	100	550	'
Shares issued for a stock option exercise at $.065 per share (in shares)	'	'	10,000	'	'
Shares issued to one warrant holder executed at a reduced price of $.125 per share	125,000	'	10,000	115,000	'
Shares issued to one warrant holder executed at a reduced price of $.125 per share (in shares)	'	'	1,000,000	'	'
Shares issued for option exercise at $.07 per share	1,190	'	170	1,020	'
Shares issued for option exercise at $.07 per share (in shares)	'	'	17,000	'	'
Shares issued for cashless warrant exercise at $.075 per share	1,167	'	1,167	'	'
Shares issued for cashless warrant exercise at $.075 per share (in shares)	'	'	116,667	'	'
Vesting expense	1,505,270	'	'	1,505,270	'
Net loss	-9,406,304	'	'	'	-9,406,304
Balance at Dec. 31, 2013	-3,218,454	'	2,199,376	23,279,585	-28,697,415
Balance (in shares) at Dec. 31, 2013	'	'	219,937,619	'	'
Value of equity instruments issued with debt	23,876	'	'	23,876	'
Shares issued for cashless warrant exercise at $.20 per share	1,296	'	1,296	'	'
Shares issued for cashless warrant exercise at $.20 per share (in shares)	'	'	129,630	'	'
Shares issued for option exercise at $.0167 per share	5,430	'	3,252	2,178	'
Shares issued for option exercise at $.0167 per share (in shares)	'	'	325,187	'	'
Shares issued at $.275 per share as Investor Relations compensation	41,250	'	1,500	39,750	'
Shares issued at $.275 per share as Investor Relations compensation (in shares)	'	'	150,000	'	'
Shares issued for cashless warrant exercise at $.17 per share	2,493	'	2,493	'	'
Shares issued for cashless warrant exercise at $.17 per share (in shares)	'	'	249,252	'	'
Shares issued for an option exercise at $.07 per share	1,400	'	200	1,200	'
Shares issued for an option exercise at $.07 per share (in shares)	'	'	20,000	'	'
Shares issued for cashless warrant exercise at $.01 per share	1,630	'	1,630	'	'
Shares issued for cashless warrant exercise at $.01 per share (in shares)	'	'	163,062	'	'
Shares issued for warrant exercise at $.18 per share	36,000	'	2,000	34,000	'
Shares issued for warrant exercise at $.18 per share (in shares)	'	'	200,000	'	'
Shares issued at $.25 per share as Investor Relations compensation	25,000	'	1,000	24,000	'
Shares issued at $.25 per share as Investor Relations compensation (in shares)	'	'	100,000	'	'
Reduction in escrow account per settlement agreement	-3,333	'	-3,333	'	'
Reduction in escrow account per settlement agreement (in shares)	'	'	-333,334	'	'
Shares issued for cashless warrant exercise at $.10 per share	3,605	'	3,605	'	'
Shares issued for cashless warrant exercise at $.10 per share (in shares)	'	'	360,444	'	'
Shares issued for cashless warrant exercise at $.075 per share	2,333	'	2,333	'	'
Shares issued for cashless warrant exercise at $.075 per share (in shares)	'	'	233,334	'	'
Shares issued for cashless warrant exercise at $.17 per share	224	'	224	'	'
Shares issued for cashless warrant exercise at $.17 per share (in shares)	'	'	22,409	'	'
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $.26 per share	0	'	728	18,191	-18,919
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $.26 per share (in shares)	'	'	72,760	'	'
Vesting expense	352,762	'	'	352,762	'
Options issued as part of employee bonus	694,500	'	'	694,500	'
Shares issued for combined cashless and cash warrant exercise @ $.15 per share.	52,500	'	5,833	46,667	'
Shares issued for combined cashless and cash warrant exercise @ $.15 per share. (in shares)	'	'	583,334	'	'
Issuance of Preferred stock	2,055,001	206	'	2,054,795	'
Shares issued to Investor Relations consultant exercisable at $.15 per share	24,000	'	1,600	22,400	'
Shares issued to Investor Relations consultant exercisable at $.15 per share (in shares)	'	'	160,000	'	'
Shares issued to Investor Relations consultant exercisable at $.25 per share	25,000	'	1,000	24,000	'
Shares issued to Investor Relations consultant exercisable at $.25 per share (in shares)	'	'	100,000	'	'
Shares issued for cashless warrant exercise at $.18 per share	2,794	'	2,794	'	'
Shares issued for cashless warrant exercise at $.18 per share (in shares)	'	'	279,366	'	'
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $.26 per share	0	'	1,169	29,232	-30,400
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Dividends as converted to common shares at $.26 per share (in shares)	'	'	116,934	'	'
Net loss	-3,352,949	'	'	'	-3,352,949
Balance at Jun. 30, 2014	($3,223,642)	$206	$2,228,700	$26,647,136	($32,099,683)
Balance (in shares) at Jun. 30, 2014	'	'	222,869,997	'	'

STATEMENT_OF_STOCKHOLDERS_DEFI1

STATEMENT OF STOCKHOLDERS' DEFICIT [Parenthetical] (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Issuance Of Common Stock To Debtors Compensation One	'	$0.15
Shares issued under PPM to five investors	'	$0.07
Issuance Of Common Stock To Debtors Compensation Two	'	$0.15
Shares issued to an institutional investor at per share	'	$0.07
Issuance Of Common Stock To Debtors Compensation Three	'	$0.07
Common stock issued to former consultant exercising option, Par value	'	$0.01
Common stock issued to former CEO exercising option, par value	'	$0.01
Shares issued upon conversion of four notes payable, par value	'	$0.15
Shares issued for interest to the four notes payable, par value	'	$0.15
Shares Issued For Cashless Exercise Of Warrants Par Value One	$0.20	$0.12
Shares Issued For Cashless Exercise Of Warrants Par Value Two	$0.17	$0.16
Shares Issued For Cashless Exercise Of Warrants Par Value Three	'	$0.15
Shares Issued For Cashless Exercise Of Warrants Par Value Four	'	$0.20
Shares Issued To Twenty Four Warrant Holders Exercised At Reduced Par Value	'	$0.10
Shares Issued To Four PPM Investors Converting Notes Par Value	'	$0.12
Shares Issued To Eleven PPM Investors Converting Notes Par Value	'	$0.18
Shares Issued To Consultant As Compensation Par Value	'	$0.38
Shares Issued For Two Note Conversions Par Value	'	$0.01
Shares Issued For Exercise Of Warrants Par Value	$0.18	$0.15
Shares Issued To Cashless Exercise Of Warrants Par Value	'	$0.17
Shares Issued To Former Board Directors As Compensation Par Value	'	$0.33
Shares Issued To One Investor For Cashless Exercise Of Warrants Par Value Two	'	$0.12
Shares Issued For Cashless Exercise Of Warrants Par Value Five	'	$0.10
Shares Issued For Interest On Conversion Of Two Note Conversions Par Value	'	$0.18
Shares Issued For Cashless Exercise Of Warrants Par Value Six	'	$0.08
Shares Issued In Settlement With Former Noteholder Par Value	'	$0.27
Shares Issued To Option Holder Par Value One	$0.17	$0.07
Shares Issued For Cashless Exercise Of Warrants Par Value Seven	'	$0.13
Shares Issued To One Warrant Holder Exercised At Reduced Par Value	'	$0.13
Shares Issued For Cashless Exercise Of Warrants Par Value Eight	'	$0.08
Shares Issued To Option Holder Par Value Two	$0.07	$0.07
Par Value Of Common Stock Issued For Ir Compensation One	$0.28	'
Shares Issued For Cashless Exercise Of Warrants Par Value Nine	$0.01	'
Shares Issued For Cashless Exercise Of Warrants Par Value Ten	$0.10	'
Shares Issued For Cashless Exercise Of Warrants Par Value Eleven	$0.08	'
Shares Issued For Cashless Exercise Of Warrants Par Value Twelve	$0.17	'
Shares Issued To Sixteen Shareholders Of Series A Convertible Preferred Stock Dividends Payable In Common Shares Par Value	$0.26	'
Shares Issued For Cashless And Cash Exercise Of Warrants Par Value	$0.15	'
Par Value Of Common Stock Issued For Investor Relations Compensation Two	$0.25	'
Stock Issued To Investor Relations Consultants Exercise Price One	$0.15	'
Stock Issued To Investor Relations Consultants Exercise Price Two	$0.25	'
Shares Issued For Cashless Exercise Of Warrants Par Value Thirteen	$0.18	'
Shares Issued To Sixteen Shareholders Of Series Convertible Preferred Stock Dividends Payable In Common Shares Par Value One	$0.26	'

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flow from operating activities:	'	'
Net loss	($3,352,949)	($3,277,061)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	25,829	141,482
Vested stock options and warrants	369,636	1,378,090
Equity instruments issued for management and consulting	111,917	67,230
Amortization of debt discount	0	92,538
(Gain) loss on valuation of equity-linked instruments	-11,468	-88,673
Changes in assets and liabilities:	'	'
Accounts receivable	-52,395	-62,180
Inventories	-238,488	37,173
Prepaid expense and other assets	-88,936	-8,176
Notes payable to shareholders	0	0
Accounts payable	563,223	-28,993
Accrued expenses	790,157	-379,465
Deferred Revenue	-64,000	5,000
Net cash used in operating activities:	-1,947,473	-2,123,035
Cash flow from investing activities:	'	'
Purchase of fixed assets	-72,377	-9,826
Purchase of intangibles	-14,782	-48,545
Net cash used in investing activities	-87,159	-58,371
Cash flow from financing activities:	'	'
Proceeds from long-term and convertible debt	125,000	1,300,000
Principal payments on notes payable	-300,000	0
Issuance of preferred stock	2,055,000	0
Issuance of common stock	92,831	1,005,333
Net cash provided by (used in) financing activities	1,972,831	2,305,333
Net increase (decrease) in cash	-61,802	123,927
Cash at beginning of period	101,953	13,139
Cash at end of period	40,151	137,066
Non cash transactions:	'	'
Debt Conversion, Converted Instrument, Amount	0	415,775
Common stock issued for accrued interest/bonus	694,500	23,394
Common stock issued to satisfy debt	0	178,568
Stock/warrant issued to satisfy accounts payable/Liabilities	$0	$43,521

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Nature of Operations and Continuance of Operations
	BioDrain Medical, Inc. (the "Company") was incorporated under the laws of the State of Minnesota in 2002. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc.  Pursuant to an Agreement and Plan of Merger dated effective December 16, 2013, the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of our proprietary cleaning fluid and filters to users of our systems. In April 2009, the Company received 510(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY FMS products.
	The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and has a stockholders’ deficit. These factors raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	Since inception to June 30, 2014, the Company has raised approximately $9,104,000 in equity, inclusive of $2,055,000 from a private placement of Series A Convertible Preferred Stock, and $4,060,000 in debt financing.  See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources”.
	Recent Accounting Developments
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers and created a new topic in the FASB Accounting Standards Codification ("ASC"), Topic 606. The new standard provides a single comprehensive revenue recognition framework for all entities and supersedes nearly all existing U.S. GAAP revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue in a manner that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and also requires enhanced disclosures. The amendments are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are currently evaluating the impact this guidance may have on our financial statements and related disclosures.
	In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders' equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company evaluated and adopted ASU 2014-10 for the reporting period ended June 30, 2014.
	In June 2014, the FASB issued ASU 2014-12, "Compensation - Stock Compensation" providing explicit guidance on how to account for share-based payments granted to employees in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. We are currently evaluating the impact this guidance may have on our financial statements.
	We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations.
	Valuation of Intangible Assets
	We review identifiable intangible assets for impairment in accordance with ASC 350- Intangibles – Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management's best estimate of the related risks and return at the time the impairment assessment is made.
	Our accounting estimates and assumptions bear various risks of change, including the length of the current economic downturn facing the United States, the expansion of the slowdown in consumer spending in the U.S. medical markets despite the early expressed opinions of financial experts that the medical market would not be as affected as other markets and failure to gain acceptance in the medical market.
	Accounting Policies and Estimates
	The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Presentation of Taxes Collected from Customers
	Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses.
	Shipping and Handling
	Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations.
	Advertising
	Advertising costs are expensed as incurred. Advertising expenses were $1,250 and $7,793 in the three and six months ended June 30, 2014 and there were no advertising expenses in the three and six months ended June 30, 2013.
	Research and Development
	Research and development costs are charged to operations as incurred. Research and development expenses were $131,285 and $249,636 in the three and six months ended June 30, 2014 and $75,264 and $133,541 for June 30, 2013.
	Revenue Recognition
	The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605-Revenue Recognition.
	Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of cleaning solution kits. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution kits may be returned. Additionally, since the Company buys both the STREAMWAY FMS units and cleaning solution kits from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur.
	Receivables
	Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements.
	Inventories
	Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows:
		June 30,		December 31,
		2014		2013
	Finished goods	$	88,285	$	56,818
	Raw materials		230,092		18,603
	Work-In-Process		42,286		46,754
	Total	$	360,663	$	122,175
	Property and Equipment
	Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows:
		Years
	Computers and office equipment	7-Mar
	Leasehold improvements	5
	Manufacturing tooling	7-Mar
	The Company’s investment in Fixed Assets consists of the following:
		June 30,		December 31,
		2014		2013
	Computers and office equipment	$	126,234	$	61,505
	Leasehold improvements		23,874		23,614
	Manufacturing tooling		97,288		89,900
	Total		247,396		175,019
	Less: Accumulated depreciation		42,738		16,909
	Total Fixed Assets, Net	$	204,658	$	158,110
	Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.
	Intangible Assets
	Intangible assets consist of trademarks and patent costs. These assets are not subject to amortization until the property patented is in production. The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified. The Company wrote-off the entire original STREAMWAY System patent of $140,588 in 2013.
	Income Taxes
	The Company accounts for income taxes in accordance with ASC 740- Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.
	The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties.
	Tax years subsequent to 2010 remain open to examination by federal and state tax authorities.
	Patents and Intellectual Property
	On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013.  The PCT makes it possible to seek patent protection for an invention simultaneously in each of 148 countries, including the United States, by filing this “international” patent application instead of filing several separate national or regional patent applications.
	Our PCT patent application is for the new model of the surgical fluid waste management system that has embodiments, based on our patent attorney’s recommendations, that are patentable over all prior art and will not infringe on any existing patents. This PCT Application adds features that are novel and non-obvious over all the Company’s previously filed applications.  A feature claimed in the Patent is the ability to maintain continuous suction to the surgical field while simultaneously measuring, recording and evacuating fluid to the facilities sewer drainage system.  This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that the unit never has to be shut off or paused during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid.
	Subsequent Events
	On July 23, 2014, Skyline Medical Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Investor Securities Purchase Agreement”) with an institutional investor (the “Investor”), pursuant to which on that date the Company issued and sold  (i) a senior convertible note, in an original principal amount of $610,978 (the “Investor Note”), which Investor Note shall be convertible into a certain amount of shares (the “Investor Conversion Shares”) of the Company’s common stock, par value $0.01 (the “Common Stock”), in accordance with the terms of the Investor Note, and (ii) a warrant (the “Investor Warrant”) to initially acquire up to 2,036,593 additional shares of Common Stock (the “Investor Warrant Shares”, and collectively with the Investor Note, the Investor Warrant and the Investor Conversion Shares, the “Investor Securities”). The aggregate purchase price was $500,000 (an approximately 22.2% original issue discount) (the “Investor Convertible Notes Offering”).
On July 23, 2014, the Company also entered into a Securities Purchase Agreement (the “SOK Securities Purchase Agreement”) with SOK Partners, LLC, an affiliate of the Company (“SOK”), pursuant to which on that date the Company issued and sold  (i) a senior convertible note, in an original principal amount of $122,196 (the “SOK Note”), which SOK Note shall be convertible into a certain amount of shares (the “SOK Conversion Shares”) of Common Stock, in accordance with the terms of the SOK Note, and (ii) a warrant (the “SOK Warrant”) to initially acquire up to 407,318 additional shares of Common Stock (the “SOK Warrant Shares”, and collectively with the SOK Note, the SOK Warrant and the SOK Conversion Shares, the “SOK Securities”). The aggregate purchase price was $100,000 (an approximately 22.2% original issue discount) (the “SOK Convertible Notes Offering”).
See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources” for a discussion of the above transactions.
Interim Financial Statements
The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company’s financial position, the results of its operations and its cash flows for the interim periods. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10-K filed with the SEC on March 27, 2014. The nature of the Company’s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.

DEVELOPMENT_STAGE_OPERATIONS

DEVELOPMENT STAGE OPERATIONS	6 Months Ended
	Jun. 30, 2014
Development Stage Enterprises [Abstract]	'
Development Stage Enterprise General Disclosures [Text Block]	'
	NOTE 2 – DEVELOPMENT STAGE OPERATIONS
	The Company was formed April 23, 2002. Since inception to August 4, 2014, 222,975,766  shares of common stock have been issued between par value and $1.67. Operations since incorporation have been devoted to raising capital, obtaining financing, development of the Company’s product, and administrative services.

STOCKHOLDERS_DEFICIT_STOCK_OPT

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	NOTE 3 – STOCKHOLDERS’ DEFICIT, STOCK OPTIONS AND WARRANTS
	The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three years. Options under this plan have terms ranging from three to ten years.
	On February 4, 2014, (the “Closing Date”) we raised $2,055,000 in gross proceeds from a private placement of Series A Convertible Preferred Stock, par value $0.01 (the “Preferred Shares”) pursuant to a Securities Purchase Agreement with certain investors (the “Purchasers”) purchased 20,550 Preferred Shares, and warrants (the “Warrants”) to acquire an aggregate of approximately 1,600,000 shares of Common Stock. The Preferred Shares are convertible into shares of Common Stock at an initial conversion price of $0.26 per share of Common Stock. The Warrants are exercisable at an exercise price of $0.325 per share and expire five years from the Closing Date. If the Common Stock is not listed on the Nasdaq Stock Market, the New York Stock Exchange, or the NYSE MKT within 180 days of the Closing, the Company shall issue additional Warrants to purchase additional shares of Common Stock, equal to 30% of the shares of Common Stock which the Preferred Shares each Purchaser purchased are convertible into. As of August 4, 2014, the Company issued additional warrants to purchase 4,615,385 shares to the Purchasers in connection with this provision.
	The Securities Purchase Agreement requires the Company to register the resale of the shares of Common Stock underlying the Preferred Shares (the “Underlying Shares”) and the Common Stock underlying the Warrants (the “Warrant Shares”). The Company is required to prepare and file a registration statement with the Securities and Exchange Commission within 132 days of the Closing Date (as extended by subsequent consent of the Purchasers), and to use commercially reasonable efforts to have the registration statement declared effective within 147 days if there is no review by the Securities and Exchange Commission, and within 192 days in the event of such review. Pursuant to the Registration Rights Agreement this deadline was extended to a filing deadline of 45 days from July 23, 2014, and an effectiveness deadline of the earlier of (A) 60 calendar days from July 23, 2014 (or 120 calendar days from July 23, 2014 if the registration is subject to review by SEC) and (B) the fifth Trading Day after the Company is notified by the SEC that the Registration Statement will not be reviewed or will not be subject to further review.
	The Preferred Shares are convertible at the option of the holder into the number of shares of Common Stock determined by dividing the stated value of the Preferred Shares being converted by the conversion price of $0.26, subject to adjustment for stock splits, reverse stock splits and similar recapitalization events. If the Company issues additional shares of Common Stock, other than certain stock that is excluded under the terms of the Securities Purchase Agreement, in one or more capital raising transactions with an aggregate purchase price of at least $100,000 for a price less than the then existing conversion price for the Preferred Shares (the “New Issuance Price”), then the then existing conversion price shall be reduced to the New Issuance Price, provided, however, that under no circumstances shall the New Issuance Price be less than $0.13 or reduced to a price level that would be in breach of the listing rules of any stock exchange or that would have material adverse effect on the Corporation’s ability to list its Common Stock on a stock exchange, including but not limited to the change of accounting treatment of the Preferred Stock. The Preferred Shares contain certain limitations on conversion so that the holder will not own more than 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of Preferred Shares held by the applicable holder, with the percentage subject to increase in certain circumstances. The Preferred Shares are eligible to vote with the Common Stock on an as-converted basis, but only to the extent that the Preferred Shares are eligible for conversion without exceeding the Beneficial Ownership Limitation. The Preferred Shares are entitled to receive dividends on a pari passu basis with the Common Stock, when, and if declared. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), after the satisfaction in full of the debts of the Company and the payment of any liquidation preference owed to the holders of shares of Common Stock ranking prior to the Preferred Shares upon liquidation, the holders of the Preferred Shares shall receive, prior and in preference to the holders of any junior securities, an amount equal to $2,055,000 times 1.2, plus all declared but unpaid dividends.
	The Warrants are exercisable on any day on or after the date of issuance, have an exercise price of $0.325 per share, subject to adjustment, and a term of five years from the date they are first exercisable. However, a holder will be prohibited from exercising a Warrant if, as a result of such exercise, the holder, together with its affiliates, would exceed the Beneficial Ownership Limitation as described above for the Preferred Shares. If any Warrant has not been fully exercised prior to the first anniversary of the Closing and if during such period the Company has not installed or received firm purchase orders (accepted by the Company) for at least 500 STREAMWAY ® Automated Surgical Fluid Disposal Systems, then, the number of shares of Common Stock for which such Warrant may be exercised shall be increased 2.5 times.
	Accounting for share-based payment
	The Company has adopted ASC 718- Compensation-Stock Compensation ("ASC 718"). Under ASC 718 stock-based employee compensation cost is recognized using the fair value based method for all new awards granted after January 1, 2006 and unvested awards outstanding at January 1, 2006. Compensation costs for unvested stock options and non-vested awards that were outstanding at January 1, 2006, are being recognized over the requisite service period based on the grant-date fair value of those options and awards, using a straight-line method. We elected the modified-prospective method under which prior periods are not retroactively restated.
	ASC 718 requires companies to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model or other acceptable means. The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future.
	Since the Company's common stock has no significant public trading history, and the Company has experienced no significant option exercises in its history, the Company is required to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company compiled historical volatilities over a period of 2 to 7 years of 15 small-cap medical companies traded on major exchanges and 10 mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach. In the case of ordinary options to employees the Company determined the expected life to be the midpoint between the vesting term and the legal term. In the case of options or warrants granted to non-employees, the Company estimated the life to be the legal term unless there was a compelling reason to make it shorter.
	When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized.
	Since the Company has limited trading history in its stock and no first-hand experience with how its investors and consultants have acted in similar circumstances, the assumptions the Company uses in calculating the fair value of stock-based payment awards represent its best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based consulting and interest expense could be materially different in the future.
	Valuation and accounting for options and warrants
	The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term.
	In January 2013, in connection with a private placement offering we issued 8% convertible one year promissory notes in an aggregate principal amount of $300,000 convertible into 2,500,000 shares of common stock assuming a conversion rate of $.12 per share and five year warrants to purchase up to an aggregate of  2,500,000 shares of the corporation’s common stock at an exercise price of $.15 per share. The value of the notes are being treated as a debt discount with an aggregate discount of $77,644, and amortized as an additional interest expense over the twelve month term of the notes. In addition, we issued to the placement agent for these sales five year warrants to purchase an aggregate of 200,000 shares of common stock at an exercise price of $.12 per share.
	In January and March 2013, in connection with a separate and new private placement offering we issued 7,142,857 shares of common stock at $.07 per share and warrants to purchase 7,142,857 shares of common stock at $.15 per share to 5 investors in return for their $500,000 investment in the Company.
	On March 15, 2013 the Company completed the private sale of 7,142,858 shares of the Company’s common stock, par value $.01 per share, at $.07 per share for an aggregate purchase price of $500,000, warrants to purchase 7,142,858 shares of common stock at an exercise price of $.08 per share, and warrants to purchase 3,571,429 shares of common stock at an exercise price of $.15 per share.
	In April 2013, the Company issued 200,000 shares of common stock, par value $.01 per share, to a former consultant exercising options; the Company issued 333,330 shares of common stock, par value $.01 per share, at $.01 per share to the former CEO exercising options.
	In May 2013, the Company converted four (4) notes totaling $156,243, plus $11,169 in interest; issued in November 2012, the noteholders received 1,116,084 shares of common stock, par value $.01, at $.10 per share. One of the noteholders was Dr. Samuel Horowitz who received 357,163 shares.
	In May and June 2013 in connection with a private placement offering we issued 8% convertible one year promissory notes in an aggregate principal amount of $1,000,000 convertible into 6,000,000 shares of common stock assuming a conversion rate of $.18 per share and five year warrants to purchase up to an aggregate of 4,611,111 shares of the corporation’s common stock at an exercise price of $.198 per share. The value of the notes net of discount was $275,640 in 2013; due in May and June 2014. In addition, we issued to the placement agent for these sales five year warrants to purchase an aggregate of 444,444 shares of common stock at an exercise price of $.18 per share.
	In August and September 2013 the Company entered into agreements with holders of certain of its outstanding warrants to purchase the Company’s common stock to amend the exercise price of the warrant to $0.10 per share in connection with the agreement of each such holder to exercise the warrants in full. Prior to the amendments, the exercise prices of such warrants ranged from $0.15 to $0.46 per share. Twenty-four warrants were exercised with a reduced exercise price, and nineteen warrants were exercised pursuant to a net exercise provision. Together such warrant exercises resulted in aggregate cash proceeds of $1,044,490 to the Company, and the issuance of an aggregate 10,444,898 shares of common stock through the reduced warrant exercise and 6,533,788 shares which were issued pursuant to a net exercise provision.
	In October 2013 the Company entered into agreements with a holder of certain of its outstanding warrants to purchase the Company’s common stock to amend the exercise price of the warrant to $.125 per share in connection with the agreement of the holder to exercise the warrants in full. Prior to the amendments, the exercise price of such warrants was $.25 per share. Two warrants were exercised with a reduced exercise price. Together the warrant exercises resulted in aggregate cash proceeds of $125,000 to the Company, and the issuance of an aggregate 1,000,000 shares of common stock.
	For grants of stock options and warrants in 2013 the Company used a 0.78% to 2.04% risk-free interest rate, 0% dividend rate, 59% or 66% volatility and estimated terms of 5 or 10 years. Value computed using these assumptions ranged from $0.119 to $0.242 per share.
	In January 2014 the Company issued 325,187 shares of common stock to the former CEO at $.0167 per share upon his exercising options.
	In January through March 2014, 9 warrant holders exercised warrants through a cashless exercise for a total of 1,158,131 shares of common stock.
	In January and February 2014 the Company issued warrants to purchase 1,615,383 shares pursuant to a February 4, 2014 private placement whereby the Company issued 20,550 shares of Series A Convertible Preferred Stock raising gross proceeds of $2,055,000. The warrants are at an exercise price of $0.325.
	In February 2014 the Company issued a warrant to purchase 111,111 shares of common stock at an exercise price of $0.27 to a major shareholder Dr. Samuel Herschkowitz. The warrant is in consideration for a bridge loan extended in December 2013 that has been paid in February 2014.
	On March 31, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of  6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $0.26 per share. As a result 72,760 shares of common stock were issued to 16 holders of Preferred Shares.
	In March 2014, the Company issued 333,334 shares of common stock to a warrant holder for a partial cash exercise at  $0.15 per share; issued 250,000 shares to the holder via the cashless exercise of the remainder of the warrant.
	In June 2014, the Company issued 279,366 shares of common stock to a warrant holder exercising cashless warrants.
	On June 30, 2014, the Company issued dividends to the Purchasers of the Preferred Shares as described above. The dividends are at an annual rate of 6% of the stated value of the Preferred Shares paid on a quarterly basis in the form of common stock per a stipulated $0.26 per share. As a result 116,934 shares of common stock were issued to 16 holders of Preferred Shares.
	On June 30, 2014, the Company issued a warrant to purchase 407,318 shares of common stock at an exercise price of $0.165 to SOK Partners, LLC, in consideration for a bridge loan. The warrant has a Black-Scholes debt discount of $23,876.
	For grants of stock options and warrants in 2014 the Company used a 1.44% to 2.75% risk-free interest rate, 0% dividend rate, 59% to 66% volatility and estimated terms of 5 to 10 years. Value computed using these assumptions ranged from $0.0586 to $0.1837 per share.
	The following summarizes transactions for stock options and warrants for the periods indicated:
			Stock Options				Warrants
			Number of	Average			Number of	Average
				Exercise				Exercise
			Shares	Price			Shares	Price
	Outstanding at December 31, 2012		12,663,566		0.09		35,132,136		0.13
	Issued		17,986,157		0.09		25,739,682		0.12
	Expired		-1,159,995		0.24		-8,326,862		0.18
	Exercised		-560,330		0.01		-17,901,127		0.11
	Outstanding at December 31, 2013		28,929,398		0.09		34,643,829		0.14
	Issued		5,115,061		0.11		2,133,812		0.27
	Expired		-495,768		0.34		-4,171,733		0.16
	Exercised		-345,187		0.02		-2,220,831		0.13
	Outstanding at June 30, 2014		33,203,504	$	0.1		30,385,077	$	0.15
	At June 30, 2014, 31,341,741 stock options are fully vested and currently exercisable with a weighted average exercise price of $0.10 and a weighted average remaining term of 8.79 years. All warrants are fully vested and exercisable. Stock-based compensation recognized for the six months ending June 2014 and June 30, 2013 was $352,762 and $1,378,541, respectively.  The Company has $259,398 of unrecognized compensation expense related to non-vested stock options that are expected to be recognized over a weighted average period of approximately  18 months.
	The following summarizes the status of options and warrants outstanding at June 30, 2014:
						Weighted
						Average
						Remaining
	Range of Exercise Prices			Shares		Life
	Options:
	$	0.01		550,000		7.02
	$	0.065		10,000		8.7
	$	0.07		177,286		9.12
	$	0.075		14,400,000		8.71
	$	0.079		1,740,508		8.72
	$	0.08		9,300,000		8.13
	$	0.088		400,000		7.57
	$	0.1325		226,415		9.04
	$	0.14		242,857		9.04
$	0.15		1,110,000		7.97
$	0.17		755,000		9.79
$	0.185		162,162		9.76
$	0.2		250,000		9.72
$	0.23		3,019,565		9.69
$	0.25		250,000		9.65
$	0.27		370,373		9.51
$	0.29		100,000		9.28
$	0.318		94,338		9.26
$	0.33		25,000		9.24
$	0.3415		20,000		9.25
Total			33,203,504
Warrants:
$	0.01		30,000		1.44
$	0.075		2,083,333		0.07
$	0.08		7,714,286		3.71
$	0.12		200,000		3.58
$	0.15		15,314,951		3.52
$	0.165		407,318		1.38
$	0.18		333,333		3.97
$	0.198		1,770,833		3.92
$	0.2		87,500		0.6
$	0.25		375,000		0.27
$	0.27		111,111		3.21
$	0.325		1,615,383		4.76
$	0.769		342,029		0.01
Total			30,385,077
Stock options and warrants expire on various dates from July 2014 to June 2024.
The shareholders approved an increase in authorized shares to 80 million shares in an annual shareholder meeting held on June 22, 2010 and approved an increase in authorized shares to 200 million shares in a special shareholder meeting held on September 7, 2011.
The shareholders approved an increase in authorized shares to 300 million shares in a special shareholder meeting held on January 15, 2013.
The shareholders approved an amendment of the Company’s 2012 Stock Incentive Plan to increase the reserve of shares authorized for issuance to 50 million shares and to increase the threshold of limitation on certain grants to 20 million shares on April 15, 2013.
An increase from 300 million to 800 million authorized shares, and an amendment of the Company’s 2012 Stock Incentive Plan to increase the reserve of shares authorized for issuance to 100 million shares was approved at the September 10, 2013 annual meeting.
Stock Options and Warrants Granted by the Company
The following table is the listing of stock options and warrants as of June 30, 2014 by year of grant:
Stock Options:
Year		Shares	Price
2010		410,000	$	0.15
2011		550,000		0.01
2012		9,477,286		.07 -.08
2013		17,901,157		.065 - .3415
2014		4,865,061		.15 –.25
Total		33,203,504	$	.01 -.3415
Warrants:
Year		Shares	Price
2008		342,029	$	0.769
2010		30,000		0.01
2011		2,458,333		.075 -.25
2012		5,352,451		.15 -.20
2013		20,068,452		.08 -.198
2014		2,133,812		.165 –.325
Total		30,385,077	$	.01 -.769

LOSS_PER_SHARE

LOSS PER SHARE	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	NOTE 4 - LOSS PER SHARE
	The following table presents the shares used in the basic and diluted loss per common share computations:
		Three Months Ended June 30,					Six Months Ended June 30,
		2014			2013		2014	2013
	Numerator:
	Net loss available in basic and diluted calculation	$	-1,735,954	$	-1,175,535	$	-3,352,949	$	-3,277,061
	Denominator:
	Weighted average common shares outstanding - basic		222,620,910		121,267,500		221,922,352		111,045,552
	Effect of diluted stock options and warrants (1)		-		-		-		-
	Weighted average common shares outstanding - basic		222,620,910		121,267,500		221,922,352		111,045,552
	Loss per common share-basic and diluted	$	-0.01	$	-0.01	$	-0.02	$	-0.03
	(1) The number of shares underlying options and warrants outstanding as of June 30, 2014 and June 30, 2013 are 63,588,581  and 84,320,276 respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

INCOME_TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	NOTE 5 – INCOME TAXES
	The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods.  Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
	There is no income tax provision in the accompanying statements of operations due to the cumulative operating losses that indicate a 100% valuation allowance for the deferred tax assets and state income taxes is appropriate.
	During September 2013, the Company experienced an "ownership change" as defined in Section 382 of the Internal Revenue Code which could potentially limit the ability to utilize the Company’s net operating losses (NOLs). The general limitation rules allow the Company to utilize its NOLs subject to an annual limitation that is determined by multiplying the federal long-term tax-exempt rate by the Company’s value immediately before the ownership change.
	At June 30, 2014, the Company had approximately $16.0 million of gross NOLs to reduce future federal taxable income, the majority of which are expected to be available for use in 2015, subject to the Section 382 limitation described above. The federal NOLs will expire beginning in 2022 if unused. The Company also had approximately $17.1 million of gross NOLs to reduce future state taxable income at June 30, 2014, which will expire in years 2022 through 2034 if unused. The Company's net deferred tax assets, which include the NOLs, are subject to a full valuation allowance. At June 30, 2014, the federal and state valuation allowances were $7.1 million and $1.5 million, respectively.
	The components of deferred income taxes at June 30, 2014 and December 31, 2013  are as follows:
		June 30,		December 31,
		2014		2013
	Deferred Tax Asset:
	Net Operating Loss	$	7,920,000	$	3,259,000
	Other		648,000		59,000
	Total Deferred Tax Asset		8,568,000		3,318,000
	Less Valuation Allowance		8,568,000		3,318,000
	Net Deferred Income Taxes	$	—	$	—

RENT_OBLIGATION

RENT OBLIGATION	6 Months Ended
	Jun. 30, 2014
Rent Obligation [Abstract]	'
Leases of Lessee Disclosure [Text Block]	'
	NOTE 6 – RENT OBLIGATION
	The Company leases its principal office under a lease that can be cancelled after three years with proper notice per the lease and an amortized schedule of adjustments that will be due to the landlord.  The lease extends five years and expires January 2018. In addition to rent, the Company pays real estate taxes and repairs and maintenance on the leased property. Rent expense was $15,447 and $33,056, for the three and six months ended June 30, 2014 and was $15,173 and $35,159 for the three and six months ended June 30, 2013 respectively.
	The Company’s rent obligation for the next five years is as follows:
	2015	$	37,000
	2016	$	38,000
	2017	$	39,000
	2018	$	3,600
	2019	$	-

LIABILITY_FOR_EQUITYLINKED_FIN

LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS	6 Months Ended
	Jun. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivative Instruments and Hedging Activities Disclosure [Text Block]	'
	NOTE 7 – LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS
	The Company adopted ASC 815- Derivatives and Hedging (“ASC 815”) on January 1, 2009. ASC 815 mandates a two-step process for evaluating whether an equity-linked financial instrument or embedded feature is indexed to the entity's own stock. It was effective for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years, which was the Company's first quarter of 2009. Many of the warrants issued by the Company contain a strike price adjustment feature, which upon adoption of ASC 815, changed the classification (from equity to liability) and the related accounting for warrants with a $479,910 estimated fair value of as of January 1, 2009. An adjustment was made to remove $486,564 from paid-in capital (the cumulative values of the warrants on their grant dates), a positive adjustment of $6,654 was made to accumulated deficit, representing the gain on valuation from the grant date to January 1, 2009, and $479,910 was booked as a liability. The warrants issued in 2011 do not contain a strike price adjustment feature and, therefore, are not treated as a liability.
	The January 1, 2009 valuation was computed using the Black-Scholes valuation model based upon a 2.5-year expected term, an expected volatility of 63%, an exercise price of $.46 per share, a stock price of $.35, a zero dividend rate and a 1.37% risk free interest rate. Subsequent to January 1, 2009 these warrants were re-valued at the end of each quarter and a gain or loss was recorded based upon their increase or decrease in value during the quarter. Likewise, new warrants that were issued during 2009 and 2010 were valued, using the Black-Scholes valuation model on their date of grant and an entry was made to reduce paid-in capital and increase the liability for equity-linked financial instruments. These warrants were also re-valued at the end of each quarter based upon their expected life, the stock price, the exercise price, assumed dividend rate, expected volatility and risk free interest rate. A significant reduction in the liability was realized in 2010 primarily due to a reduction from $.50 to $.22 per share in the underlying stock price. The Company realized a slight increase in the liability for existing warrants during the first quarter of 2012. In 2013 there was a significant decrease in the liability primarily due to current expirations and the amount of warrants reaching expiration in the near term. In the first quarter 2014 the liability continued to decrease, and was stable in the second quarter 2014.
	The inputs to the Black-Scholes model during 2009 through 2014 were as follows:
	Stock price		$ .06 to $.50
	Exercise price		$ .01 to $.325
	Expected life		2.0 to 6.5 years
	Expected volatility		59%
	Assumed dividend rate		- %
	Risk-free interest rate		.13% to 2.97%
	The original valuations, annual gain/(loss) and end of year valuations are shown below:
														Value at		2012 Gain		Value		2013 Gain		Value		2014 Gain		Value at
		Initial Value		Annual Gain (Loss)		Value at 12/31/09		2010 Gain (Loss)		Value at 12/31/10		2011 Gain (Loss)		12/31/11		(Loss)		at 12/31/2012		(Loss)		at 12/31/2013		(Loss)		6/30/14
	January 1, 2009 adoption	$	479,910	$	-390,368	$	870,278	$	868,772	$	1,506	$	-88,290	$	89,796	$	-21,856	$	111,652	$	100,053	$	11,599	$	11,469	$	130
	Warrants issued in quarter ended 6/30/2009		169,854		20,847		149,007		147,403		1,604		-4,689		6,293		6,293		-		-		-		-		-
	Warrants issued in quarter ended 9/30/2009		39,743		-738		40,481		40,419		62		-1,562		1,624		910		714		714		-		-		-
	Warrants issued in quarter ended 12/31/2009		12,698		617		12,081		12,053		28		-724		752		415		337		337		-		-		-
	Subtotal		702,205				1,071,847
	Warrants issued in quarter ended 3/31/2010		25,553						25,014		539		-5,570		6,109		3,701		2,408		2,408		-		-		-
	Warrants issued in quarter ended 6/30/2010		31,332						30,740		592		-6,122		6,714		6,083		631		631		-		-		-
	Warrants issued in quarter ended 9/30/2010		31,506						20,891		10,615		-44,160		54,775		1,338		53,437		53,437		-		-		-
	Total	$	790,596	$	-369,642	$	1,071,847	$	1,145,292	$	14,946	$	-151,117	$	166,063	$	-3,116	$	169,179	$	157,580	$	11,599	$	11,469	$	130

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	NOTE 8 – RELATED PARTY TRANSACTIONS
	The Company, entered into agreements, in 2008, with our Chairman of the Board, Lawrence Gadbaw, and in 2009 with a board member, Peter Morawetz, to pay Mr. Gadbaw $25,000 and Dr. Morawetz $30,000 upon the Company raising $3 million in new equity. Mr. Gadbaw received 277,778 shares at $.09 per share in June 2012 as compensation in lieu of the $25,000 cash for raising $3 million in new equity. Mr. Gadbaw was paid the balance due under his separation agreement from 2008. This amount was $46,000 upon signing the agreement in 2008 payable at $2,000 per month; the payments to Mr. Gadbaw are complete. Mr. Gadbaw also received a warrant for 30,000 shares at $.15 per share on June 30, 2012 as compensation for service as Chairman. Mr. Gadbaw and Dr. Morawetz have both resigned from the Board in the third quarter of 2013. Both Mr. Gadbaw and Dr. Morawetz received 50,000 shares of common stock each at $.325 per share; 20,000 of these shares were for compensation from serving as Board members and the remaining 30,000 shares were issued to satisfy previous contractual agreements.
	Convertible Note Issuances to Dr. Samuel Herschkowitz and SOK Partners, LLC
	On July 23, 2014, the Company also entered into a Securities Purchase Agreement (the “SOK Securities Purchase Agreement”) with SOK Partners, LLC, an affiliate of the Company (“SOK”), pursuant to which the Company agreed to issue and sell (i) a senior convertible note, in an original principal amount of $122,195.60 (the “SOK Note”), which SOK Note shall be convertible into a certain amount of shares (the “SOK Conversion Shares”) of Common Stock, in accordance with the terms of the SOK Note, and (ii) a warrant (the “SOK Warrant”) to initially acquire up to 407,318 additional shares of Common Stock (the “SOK Warrant Shares”, and collectively with the SOK Note, the SOK Warrant and the SOK Conversion Shares, the “SOK Securities”) for an aggregate purchase price of $100,000 (an approximately 22.2% original issue discount) (the “SOK Convertible Notes Offering”).
	The SOK Note, the SOK Warrant, the SOK Securities Purchase Agreement and the SOK Registration Rights Agreement contain terms and conditions substantially identical to that of the Investor Note, the Investor Warrant, the Investor Securities Purchase Agreement and the Investor Registration Rights Agreement (as defined below), respectively, which are described in greater detail under “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources”.
	On September 11, 2013, both the Herschkowitz Note and the SOK Note (each as defined below in this Note 8) were converted in full by the holders thereof at $0.014 per share. The principal and interest balance of the Herschkowitz Note of $314,484 was converted into 22,463,172 shares of common stock. The principal and interest balance of the SOK Note of $680,444 was converted into 48,603,721 shares of common stock. The collateral that secured these notes was released back to the Company.
	The remaining disclosure of this Note 8 provides historical information regarding the Herschkowitz Note, the SOK Note and certain other convertible note issuances.
	On March 28, 2012, the Company, entered into a Convertible Note Purchase Agreement, dated as of March 28, 2012 (the “SOK Purchase Agreement”) with SOK Partners, LLC (“SOK Partners”), and an investment partnership. Josh Kornberg, who is a member of the Company’s Board of Directors, and Dr. Samuel Herschkowitz are affiliates of the manager of SOK Partners and Ricardo Koenigsberger, a director, is a holder of membership units of SOK Partners. Pursuant to the SOK Purchase Agreement, the Company issued a 20.0% convertible note due August 2012 in the principal amount of up to $600,000. Principal and accrued interest on the note is due and payable on August 28, 2012. The Company’s obligations under the note are secured by the grant of a security interest in substantially all tangible and intangible assets of the Company. The SOK Purchase Agreement and the note include customary events of default that include, among other things, non-payment defaults, covenant defaults, inaccuracy of representations and warranties, cross-defaults to other indebtedness and bankruptcy and insolvency defaults. The occurrence of an event of default could result in the acceleration of the Company’s obligations under the note, and interest rate of twenty-four (24%) percent per annum accrues if the note is not paid when due.
	On March 28, 2012, the Company received an advance of $84,657 under the note, including a cash advance of $60,000 net of a prepayment of interest on the first $300,000 in advances under the note. The holder of the note is entitled to convert the note into shares of common stock of the Company at an initial conversion price per share of $0.065 per share, subject to adjustment in the event of (1) certain issuances of common stock or convertible securities at a price lower than the conversion price of the note, and (2) recapitalizations, stock splits, reorganizations and similar events. In addition, the Company is required to issue two installments of an equity bonus to SOK Partners in the form of common stock valued at the rate of $0.065 per share. In March 2012, the Company issued the first equity bonus to SOK Partners, consisting of 4,615,385 shares of common stock, with a second installment due within five business days after SOK Partners has made aggregate advances under the note of at least $300,000. In May 2012 the Company issued the second installment consisting of 4,615,385 shares of common stock subsequent to SOK Partners surpassing the aggregate advances of $300,000. Until the maturity date of the note, if the Company obtains financing from any other source without the consent of SOK Partners, then the Company is required to issue additional bonus equity in an amount equal to $600,000 less the aggregate advances on the note made prior to the breach. The principal balance of the SOK Note was $357,282 as of December 31, 2012.
	As long as any amount payable under the SOK Note remains outstanding, SOK Partners or its designee is entitled to appoint a new member to the Company’s Board of Directors, who will be appointed upon request. Mr. Koenigsberger was appointed to the Board by SOK Partners on June 25, 2012.
	On March 28, 2012, the Company signed an Amended and Restated Note Purchase Agreement, dated as of December 20, 2011, with Dr. Samuel Herschkowitz (as amended, the “Herschkowitz Purchase Agreement”). Pursuant to the Herschkowitz Purchase Agreement, the Company issued a 20.0% convertible note due June 20, 2012 in the principal amount of $240,000 for previous advances under the note. The Company’s obligations under the note are secured by the grant of a security interest in substantially all tangible and intangible assets of the Company. The Company has previously issued to Dr. Herschkowitz an equity bonus consisting of 1,546,667 shares of common stock. An additional 7,500,000 shares were transferred to Dr. Herschkowitz effective in April 2012, upon the occurrence of an event of default on the note. On August 13, 2012, the Company entered into a settlement and forbearance agreement described below, relating to the defaults under the Herschkowitz Note and other matters.
	As long as any amount payable under the Herschkowitz Note remains outstanding, Dr. Herschkowitz or his designee is entitled to appoint a special advisor to the Company’s Board of Directors, to be appointed as a member upon request. Pursuant to this authority, Josh Kornberg was appointed to the Board on March 9, 2012. In addition, pursuant to this authority, Mr. Koenigsberger was appointed to the Board on June 25, 2012.
	Pursuant to a letter dated April 12, 2012, Dr. Herschkowitz advised the Company of the occurrence of numerous events of default under the terms of the Herschkowitz Note and the Herschkowitz Note Purchase Agreement. As a result of such events of default, Dr. Herschkowitz asserted significant rights as a secured creditor of the Company, including his rights as a secured creditor with a security interest in substantially all assets of the Company. Without a settlement relating to the defaults and other matters, Dr. Herschkowitz could have taken action to levy upon the Company’s assets, including patents and other intellectual property.
	In addition, the Company and Atlantic Partners Alliance LLC (“APA”) were parties to a letter agreement dated March 14, 2012, providing APA and its affiliates (including Dr. Herschkowitz and SOK) with rights to avoid dilution relating to additional issuances of equity securities by the Company through July 14, 2012, evidencing the parties’ intent that APA would be provided with significant protection against dilution. This protection was in recognition of APA’s investments in the Company involving a high degree of risk and the Company’s contemplated need for restructuring its indebtedness, which were anticipated to result, and have resulted, in significant dilution. The parties acknowledged that Dr. Herschkowitz and SOK would not have made their historical cash investments in the Company to the same degree had the dilution protection not been provided, and the investments by these parties have enabled the Company to avoid insolvency. Since the respective dates of the Herschkowitz Note Purchase Agreement and the SOK Note Purchase Agreement, the Company had issued in excess of 16,000,000 shares of common stock to parties other than APA and its affiliates, resulting in significant dilution.
	Effective August 15, 2012, the Company entered into a letter agreement with Dr. Herschkowitz, APA and SOK (the “Forbearance Agreement”). Under the Forbearance Agreement, among other things, (i) Dr. Herschkowitz agreed to forbear from asserting his rights as a secured creditor to substantially all of the Company’s assets, resulting from the Company’s defaults; (ii) the Company issued an aggregate 26.5 million shares of common stock to Dr. Herschkowitz and SOK and adjusted the conversion price of their convertible notes to $0.014 per share from $0.065 per share, to satisfy the Company’s obligations to adjust for dilution; (iii) Dr. Herschkowitz and SOK agreed to extend the maturity of their notes to December 31, 2012; (iv) the Company agreed to pay certain compensation to Dr. Herschkowitz upon the achievement of financial milestones and (v) Dr. Herschkowitz clarified and waived certain of his rights, including the right to interest at a penalty rate upon default.
	In the Forbearance Agreement, Dr. Herschkowitz agreed to forbear from exercising any of his rights arising under the Herschkowitz Note or the Herschkowitz Note Purchase Agreement with respect to the existing defaults against the Company, subject to the limitations set forth in the letter agreement and without releasing or waiving any future breach of the letter agreement. He further agreed to forbear from exercising any rights with respect to events of default, security interests in the collateral and other similar remedies against the Company or his interests under the Herschkowitz Note or the Herschkowitz Note Purchase Agreement until the occurrence of an event of default under the Herschkowitz Note: (a) that does not constitute an existing default and (b) occurs and accrues after the date of the letter agreement.
	Dr. Herschkowitz and the Company acknowledged that 7.5 million shares of the Company’s common stock, constituting the “penalty shares” under the Herschkowitz Note Purchase Agreement, were delivered to Dr. Herschkowitz in April 2012 as provided in the Herschkowitz Note Purchase Agreement upon an event of default. Notwithstanding a provision that would have increased the rate of interest from 20% to 24% upon an event of default, Dr. Herschkowitz agreed that the Company would not pay the increased rate of interest but would accrue interest at 20% until a subsequent event of default.
	Under the Forbearance Agreement, the Herschkowitz Note and the SOK Note were amended as follows: (i) the due dates of the notes were extended to December 31, 2012 from the previous due dates of June 20, 2012 and August 28, 2012, respectively; (ii) Dr. Herschkowitz will release his security agreement after payment of all currently outstanding promissory notes to parties other than SOK; and (iii) the Herschkowitz Note was amended to add certain events of default relating to judgments against the Company or other creditors taking action with respect to the collateral. In consideration of the extension additional milestone fees were revised as described below. Pursuant to a Forbearance and Settlement Agreement with these parties dated August 15, 2012, as subsequently amended, the due date of these notes were extended to August 31, 2013.
	APA and its affiliates agreed to terminate the letter agreement regarding dilution dated March 14, 2012. In consideration of the various provisions of the letter agreement and in recognition of the understanding of the parties regarding dilution and the agreements of APA and its affiliates to forbear and to extend the due dates of the notes, the Company (i) issued 13,250,000 shares to Dr. Herschkowitz, (ii) issued 13,250,000 shares to SOK, and (iii) the conversion price of the Herschkowitz Note and the SOK Note, respectively was changed to $0.014 per share from $0.065 per share.
	In the event that the Company consummated the following series of transactions on or prior to June 30, 2013: (i) a merger or similar transaction with a public shell company, (ii) raising between $2 million and $4 million through an offering of the securities of the public shell company concurrent with or subsequent to the shell merger and (iii) listing the Company’s shares on NASDAQ pursuant to an underwritten offering of the Company’s securities resulting in gross proceeds of between $5 million and $30 million, then the Company would have to be required to deliver to Dr. Herschkowitz the following compensation: (A) $75,000 upon consummating the shell merger, (B) $150,000 upon consummating the qualifying financing round and (C) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $1,000,000. The Company was also required to reimburse Dr. Herschkowitz at his actual out-of-pocket cost for reasonable expenses incurred in connection with the shell transactions, with a maximum limit of $10,000 for such expenses.
	In connection with the extension of the due date for the Herschkowitz Note and the SOK Note on March 6, 2013, the milestone fees were revised. The following fees were payable to Dr. Herschkowitz in the event that the Company consummates the following series of transactions on or prior to December 31, 2013: (i) financing raising not less than $1 million, compensation of $75,000; (ii) a going private transaction, compensation of $200,000 or greater and (iii) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $3,000,000. In May 2013 Dr. Herschkowitz received $75,000 after the Company surpassed raising $1 million.
	As a result of the transactions under the Forbearance Agreement and other investments, Dr. Herschkowitz, SOK and their affiliates currently own shares of common stock and securities representing beneficial ownership of more than 57% of the Company’s outstanding common stock, giving such parties significant control over election of the Board of Directors and other matters.
	On November 6, 2012, the Company issued and sold convertible promissory notes in the total principal amount of $156,243 to Dr. Herschkowitz and certain of his assignees.  The Company issued to these parties an aggregate 1,562,430 shares of common stock in consideration of placement of the notes. The notes bear interest at a rate of 20% per annum and are secured by a security interest in the Company’s accounts receivable, patents and certain patent rights and are convertible into common stock upon certain mergers or other fundamental transactions at a conversion price based on the trading price prior to the transaction. The proceeds from this transaction were used to pay off approximately $155,000 in principal amount of secured indebtedness. Such notes were converted in April 2013 in to 1,041,622 shares of common stock at $.10 per share.
	In December 2013, the Company received an additional $300,000 in debt financing from SOK Partners under a non-convertible grid note due February 28, 2014, with 10% interest based on a 365 day year. Dr. Herschkowitz received 10% of the gross proceeds in advance, and the Company received $250,000 in three tranches in December 2013. In January 2014, the Company received an additional $20,000 from SOK Partners completing the grid note maximum. Should the company default on the note the interest rate will increase to 20% interest based on a 365 day year.  In February 2014, the Company paid $305,589.04 to SOK Partners in complete payment of the grid note, including interest.
	In connection with the sale of the Preferred Shares on February 4, 2014 as described in Note 3, Josh Kornberg, our CEO, was one of the Purchasers. Mr. Kornberg purchased 19,231 Preferred Shares for a purchase price of $25,000 and received warrants to purchase 3,846 shares of common stock.

Retirement_Savings_Plan

Retirement Savings Plan	6 Months Ended
	Jun. 30, 2014
Compensation and Retirement Disclosure [Abstract]	'
Pension and Other Postretirement Benefits Disclosure [Text Block]	'
	Note 9 – Retirement Savings Plan
	We have a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) of the Internal Revenue Code, which covers employees meeting certain eligibility requirements. In fiscal 2012, 2013 and again in 2014, we matched 100%, of the employee’s contribution up to 4% of their earnings. The employer contribution was $8,171 and $12,304 for the three months ending June 30, 2014 and June 30, 2013, respectively, and was $15,494 and $18,097, for the six months ending June 30, 2014 and June 30, 2013, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 10 – Commitments and Contingencies
	On July 17, 2014, Skyline Medical Inc. (the “Company”) and a stockholder entered into a settlement agreement and release (the “Settlement Agreement”) with Marshall Ryan (“Ryan”) and a company related to Ryan (together, the “Plaintiffs”). The settlement relates to a previously disclosed lawsuit by the Plaintiffs initiated in March 2014. Ryan is an engineer who previously worked with the Company on design of certain of the Company’s products. The lawsuit alleged among other things, breach of a 2008 consulting agreement, a 2006 manufacturing agreement and a 2006 supply agreement among the Plaintiffs and the Company, various claims of fraud and negligent misrepresentation, and breach of the duty of good faith and fair dealing.
	Under the Settlement Agreement, the parties have agreed that the lawsuit will be dismissed. The Company has agreed to pay Ryan an aggregate of $500,000 in various cash installments through April 25, 2015, which amount includes $200,000 in installments that are payable during the remainder of 2014. The Settlement Agreement, among other things, extinguishes any prior claims of Plaintiffs for royalties or other alleged rights to payments under their prior agreements with the Company. Payment of the outstanding balance under the Settlement Agreement will be accelerated if the Company raises $2 million or more of gross dollars in a single funding round or raises aggregate funding of $4 million of gross dollars on or before April 10, 2015. If the Company defaults on the required cash payments and fails to cure as provided in the Settlement Agreement, then Ryan will have the option to either sue Skyline to enforce the Settlement Agreement or rescind the Settlement Agreement, including returning all payments previously made thereunder.
	The Settlement Agreement also contains mutual releases covering claims other than a breach of the Settlement Agreement. In the Settlement Agreement, Ryan fully, unconditionally and irrevocably affirms and ratifies the Company’s rights to Ryan’s prior patent assignments, and disclaims any right, title or interest in the Company’s Streamway product including any claims to royalties both past and future. In addition, the parties confirmed that the patents related to the Streamway product belong exclusively to Skyline and remain in full force and effect.

Supplemental_Cash_Flow_Data

Supplemental Cash Flow Data	6 Months Ended
	Jun. 30, 2014
Supplemental Cash Flow Elements [Abstract]	'
Cash Flow, Supplemental Disclosures [Text Block]	'
	Note 11 – Supplemental Cash Flow Data
	Cash payments for interest were   $3,468 and $15,522 for the three months ended June 30, 2014 and June 30, 2013, and $21,606 and $41,930 for the six months ended June 30, 2014 and June 30, 2013.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis Of Accounting Policy [Policy Text Block]	'
	Nature of Operations and Continuance of Operations
	BioDrain Medical, Inc. (the "Company") was incorporated under the laws of the State of Minnesota in 2002. Effective August 6, 2013, the Company changed its name to Skyline Medical Inc.  Pursuant to an Agreement and Plan of Merger dated effective December 16, 2013, the Company merged with and into a Delaware corporation with the same name that was its wholly-owned subsidiary, with such Delaware Corporation as the surviving corporation of the merger. The Company has developed an environmentally safe system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company also makes ongoing sales of our proprietary cleaning fluid and filters to users of our systems. In April 2009, the Company received 510(k) clearance from the FDA to authorize the Company to market and sell its STREAMWAY FMS products.
	The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and has a stockholders’ deficit. These factors raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	Since inception to June 30, 2014, the Company has raised approximately $9,104,000 in equity, inclusive of $2,055,000 from a private placement of Series A Convertible Preferred Stock, and $4,060,000 in debt financing.  See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources”.
New Accounting Pronouncements Policy [Policy Text Block]	'
	Recent Accounting Developments
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers and created a new topic in the FASB Accounting Standards Codification ("ASC"), Topic 606. The new standard provides a single comprehensive revenue recognition framework for all entities and supersedes nearly all existing U.S. GAAP revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue in a manner that depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and also requires enhanced disclosures. The amendments are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are currently evaluating the impact this guidance may have on our financial statements and related disclosures.
	In June 2014, the FASB issued ASU 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements. ASU 2014-10 eliminates the distinction of a development stage entity and certain related disclosure requirements, including the elimination of inception-to-date information on the statements of operations, cash flows and stockholders' equity. The amendments in ASU 2014-10 will be effective prospectively for annual reporting periods beginning after December 15, 2014, and interim periods within those annual periods, however early adoption is permitted. The Company evaluated and adopted ASU 2014-10 for the reporting period ended June 30, 2014.
	In June 2014, the FASB issued ASU 2014-12, "Compensation - Stock Compensation" providing explicit guidance on how to account for share-based payments granted to employees in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. The amendments in this Update are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. We are currently evaluating the impact this guidance may have on our financial statements.
	We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations.
Valuation Of Intangible Assets [Policy Text Block]	'
	Valuation of Intangible Assets
	We review identifiable intangible assets for impairment in accordance with ASC 350- Intangibles – Goodwill and Other, whenever events or changes in circumstances indicate the carrying amount may not be recoverable. Our intangible assets are currently solely the costs of obtaining trademarks and patents. Events or changes in circumstances that indicate the carrying amount may not be recoverable include, but are not limited to, a significant change in the medical device marketplace and a significant adverse change in the business climate in which we operate. If such events or changes in circumstances are present, the undiscounted cash flows method is used to determine whether the intangible asset is impaired. Cash flows would include the estimated terminal value of the asset and exclude any interest charges. If the carrying value of the asset exceeds the undiscounted cash flows over the estimated remaining life of the asset, the asset is considered impaired, and the impairment is measured by reducing the carrying value of the asset to its fair value using the discounted cash flows method. The discount rate utilized is based on management's best estimate of the related risks and return at the time the impairment assessment is made.
	Our accounting estimates and assumptions bear various risks of change, including the length of the current economic downturn facing the United States, the expansion of the slowdown in consumer spending in the U.S. medical markets despite the early expressed opinions of financial experts that the medical market would not be as affected as other markets and failure to gain acceptance in the medical market.
Use of Estimates, Policy [Policy Text Block]	'
	Accounting Policies and Estimates
	The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Presentation Of Taxes Collected From Customers Policy [Policy Text Block]	'
	Presentation of Taxes Collected from Customers
	Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses.
Shipping and Handling Cost, Policy [Policy Text Block]	'
	Shipping and Handling
	Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations.
Advertising Costs, Policy [Policy Text Block]	'
	Advertising
	Advertising costs are expensed as incurred. Advertising expenses were $1,250 and $7,793 in the three and six months ended June 30, 2014 and there were no advertising expenses in the three and six months ended June 30, 2013.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development
	Research and development costs are charged to operations as incurred. Research and development expenses were $131,285 and $249,636 in the three and six months ended June 30, 2014 and $75,264 and $133,541 for June 30, 2013.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 Revenue Recognition and ASC 605-Revenue Recognition.
	Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY FMS units as well as shipments of cleaning solution kits. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one-year warranty whereby the Company replaces or repairs, at its option, and it would be rare that the STREAMWAY FMS unit or significant quantities of cleaning solution kits may be returned. Additionally, since the Company buys both the STREAMWAY FMS units and cleaning solution kits from “turnkey” suppliers, the Company would have the right to replacements from the suppliers if this situation should occur.
Receivables, Policy [Policy Text Block]	'
	Receivables
	Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements.
Inventory, Policy [Policy Text Block]	'
	Inventories
	Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows:
		June 30,		December 31,
		2014		2013
	Finished goods	$	88,285	$	56,818
	Raw materials		230,092		18,603
	Work-In-Process		42,286		46,754
	Total	$	360,663	$	122,175
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property and Equipment
	Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows:
		Years
	Computers and office equipment	7-Mar
	Leasehold improvements	5
	Manufacturing tooling	7-Mar
	The Company’s investment in Fixed Assets consists of the following:
		June 30,		December 31,
		2014		2013
	Computers and office equipment	$	126,234	$	61,505
	Leasehold improvements		23,874		23,614
	Manufacturing tooling		97,288		89,900
	Total		247,396		175,019
	Less: Accumulated depreciation		42,738		16,909
	Total Fixed Assets, Net	$	204,658	$	158,110
	Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred.
Intangible Assets Policy [Policy Text Block]	'
	Intangible Assets
	Intangible assets consist of trademarks and patent costs. These assets are not subject to amortization until the property patented is in production. The assets are reviewed for impairment annually, and impairment losses, if any, are charged to operations when identified. The Company wrote-off the entire original STREAMWAY System patent of $140,588 in 2013.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	The Company accounts for income taxes in accordance with ASC 740- Income Taxes (“ASC 740”). Under ASC 740, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.
	The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties.
	Tax years subsequent to 2010 remain open to examination by federal and state tax authorities.
Patents and Intellectual Property Policy [Policy Text Block]	'
	Patents and Intellectual Property
	On January 25th, 2014 the Company filed a non-provisional PCT Application No. PCT/US2014/013081 claiming priority from the U.S. Provisional Patent Application, number 61756763 which was filed one year earlier on January 25th, 2013.  The PCT makes it possible to seek patent protection for an invention simultaneously in each of 148 countries, including the United States, by filing this “international” patent application instead of filing several separate national or regional patent applications.
	Our PCT patent application is for the new model of the surgical fluid waste management system that has embodiments, based on our patent attorney’s recommendations, that are patentable over all prior art and will not infringe on any existing patents. This PCT Application adds features that are novel and non-obvious over all the Company’s previously filed applications.  A feature claimed in the Patent is the ability to maintain continuous suction to the surgical field while simultaneously measuring, recording and evacuating fluid to the facilities sewer drainage system.  This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that the unit never has to be shut off or paused during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid.
Subsequent Events, Policy [Policy Text Block]	'
	Subsequent Events
	On July 23, 2014, Skyline Medical Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Investor Securities Purchase Agreement”) with an institutional investor (the “Investor”), pursuant to which on that date the Company issued and sold  (i) a senior convertible note, in an original principal amount of $610,978 (the “Investor Note”), which Investor Note shall be convertible into a certain amount of shares (the “Investor Conversion Shares”) of the Company’s common stock, par value $0.01 (the “Common Stock”), in accordance with the terms of the Investor Note, and (ii) a warrant (the “Investor Warrant”) to initially acquire up to 2,036,593 additional shares of Common Stock (the “Investor Warrant Shares”, and collectively with the Investor Note, the Investor Warrant and the Investor Conversion Shares, the “Investor Securities”). The aggregate purchase price was $500,000 (an approximately 22.2% original issue discount) (the “Investor Convertible Notes Offering”).
	On July 23, 2014, the Company also entered into a Securities Purchase Agreement (the “SOK Securities Purchase Agreement”) with SOK Partners, LLC, an affiliate of the Company (“SOK”), pursuant to which on that date the Company issued and sold  (i) a senior convertible note, in an original principal amount of $122,196 (the “SOK Note”), which SOK Note shall be convertible into a certain amount of shares (the “SOK Conversion Shares”) of Common Stock, in accordance with the terms of the SOK Note, and (ii) a warrant (the “SOK Warrant”) to initially acquire up to 407,318 additional shares of Common Stock (the “SOK Warrant Shares”, and collectively with the SOK Note, the SOK Warrant and the SOK Conversion Shares, the “SOK Securities”). The aggregate purchase price was $100,000 (an approximately 22.2% original issue discount) (the “SOK Convertible Notes Offering”).
	See “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources” for a discussion of the above transactions.
Interim Financial Statements Policy [Policy Text Block]	'
	Interim Financial Statements
	The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company’s financial position, the results of its operations and its cash flows for the interim periods. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10-K filed with the SEC on March 27, 2014. The nature of the Company’s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. Inventory balances are as follows:
		June 30,		December 31,
		2014		2013
	Finished goods	$	88,285	$	56,818
	Raw materials		230,092		18,603
	Work-In-Process		42,286		46,754
	Total	$	360,663	$	122,175
Property, Plant and Equipment [Table Text Block]	'
	The Company’s investment in Fixed Assets consists of the following:
		June 30,		December 31,
		2014		2013
	Computers and office equipment	$	126,234	$	61,505
	Leasehold improvements		23,874		23,614
	Manufacturing tooling		97,288		89,900
	Total		247,396		175,019
	Less: Accumulated depreciation		42,738		16,909
	Total Fixed Assets, Net	$	204,658	$	158,110

STOCKHOLDERS_DEFICIT_STOCK_OPT1

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following summarizes transactions for stock options and warrants for the periods indicated:
			Stock Options				Warrants
			Number of	Average			Number of	Average
				Exercise				Exercise
			Shares	Price			Shares	Price
	Outstanding at December 31, 2012		12,663,566		0.09		35,132,136		0.13
	Issued		17,986,157		0.09		25,739,682		0.12
	Expired		-1,159,995		0.24		-8,326,862		0.18
	Exercised		-560,330		0.01		-17,901,127		0.11
	Outstanding at December 31, 2013		28,929,398		0.09		34,643,829		0.14
	Issued		5,115,061		0.11		2,133,812		0.27
	Expired		-495,768		0.34		-4,171,733		0.16
	Exercised		-345,187		0.02		-2,220,831		0.13
	Outstanding at June 30, 2014		33,203,504	$	0.1		30,385,077	$	0.15
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]	'
	The following summarizes the status of options and warrants outstanding at June 30, 2014:
						Weighted
						Average
						Remaining
	Range of Exercise Prices			Shares		Life
	Options:
	$	0.01		550,000		7.02
	$	0.065		10,000		8.7
	$	0.07		177,286		9.12
	$	0.075		14,400,000		8.71
	$	0.079		1,740,508		8.72
	$	0.08		9,300,000		8.13
	$	0.088		400,000		7.57
	$	0.1325		226,415		9.04
	$	0.14		242,857		9.04
	$	0.15		1,110,000		7.97
	$	0.17		755,000		9.79
	$	0.185		162,162		9.76
	$	0.2		250,000		9.72
	$	0.23		3,019,565		9.69
	$	0.25		250,000		9.65
	$	0.27		370,373		9.51
	$	0.29		100,000		9.28
	$	0.318		94,338		9.26
	$	0.33		25,000		9.24
	$	0.3415		20,000		9.25
	Total			33,203,504
	Warrants:
	$	0.01		30,000		1.44
	$	0.075		2,083,333		0.07
	$	0.08		7,714,286		3.71
	$	0.12		200,000		3.58
	$	0.15		15,314,951		3.52
	$	0.165		407,318		1.38
	$	0.18		333,333		3.97
	$	0.198		1,770,833		3.92
	$	0.2		87,500		0.6
	$	0.25		375,000		0.27
	$	0.27		111,111		3.21
	$	0.325		1,615,383		4.76
	$	0.769		342,029		0.01
	Total			30,385,077
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]	'
	The following table is the listing of stock options and warrants as of June 30, 2014 by year of grant:
	Stock Options:
	Year		Shares	Price
	2010		410,000	$	0.15
	2011		550,000		0.01
	2012		9,477,286		.07 -.08
	2013		17,901,157		.065 - .3415
	2014		4,865,061		.15 –.25
	Total		33,203,504	$	.01 -.3415
	Warrants:
	Year		Shares	Price
	2008		342,029	$	0.769
	2010		30,000		0.01
	2011		2,458,333		.075 -.25
	2012		5,352,451		.15 -.20
	2013		20,068,452		.08 -.198
	2014		2,133,812		.165 –.325
	Total		30,385,077	$	.01 -.769

LOSS_PER_SHARE_Tables

LOSS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The following table presents the shares used in the basic and diluted loss per common share computations:
		Three Months Ended June 30,					Six Months Ended June 30,
		2014			2013		2014	2013
	Numerator:
	Net loss available in basic and diluted calculation	$	-1,735,954	$	-1,175,535	$	-3,352,949	$	-3,277,061
	Denominator:
	Weighted average common shares outstanding - basic		222,620,910		121,267,500		221,922,352		111,045,552
	Effect of diluted stock options and warrants (1)		-		-		-		-
	Weighted average common shares outstanding - basic		222,620,910		121,267,500		221,922,352		111,045,552
	Loss per common share-basic and diluted	$	-0.01	$	-0.01	$	-0.02	$	-0.03
	(1) The number of shares underlying options and warrants outstanding as of June 30, 2014 and June 30, 2013 are 63,588,581  and 84,320,276 respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

INCOME_TAXES_Tables

INCOME TAXES (Tables)	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	The components of deferred income taxes at June 30, 2014 and December 31, 2013  are as follows:
		June 30,		December 31,
		2014		2013
	Deferred Tax Asset:
	Net Operating Loss	$	7,920,000	$	3,259,000
	Other		648,000		59,000
	Total Deferred Tax Asset		8,568,000		3,318,000
	Less Valuation Allowance		8,568,000		3,318,000
	Net Deferred Income Taxes	$	—	$	—

RENT_OBLIGATION_Tables

RENT OBLIGATION (Tables)	6 Months Ended
	Jun. 30, 2014
Rent Obligation [Abstract]	'
Schedule of Rent Expense [Table Text Block]	'
	The Company’s rent obligation for the next five years is as follows:
	2015	$	37,000
	2016	$	38,000
	2017	$	39,000
	2018	$	3,600
	2019	$	-

LIABILITY_FOR_EQUITYLINKED_FIN1

LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS (Tables)	6 Months Ended
	Jun. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	'
	The inputs to the Black-Scholes model during 2009 through 2014 were as follows:
	Stock price		$ .06 to $.50
	Exercise price		$ .01 to $.325
	Expected life		2.0 to 6.5 years
	Expected volatility		59%
	Assumed dividend rate		- %
	Risk-free interest rate		.13% to 2.97%
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
	The original valuations, annual gain/(loss) and end of year valuations are shown below:
														Value at		2012 Gain		Value		2013 Gain		Value		2014 Gain		Value at
		Initial Value		Annual Gain (Loss)		Value at 12/31/09		2010 Gain (Loss)		Value at 12/31/10		2011 Gain (Loss)		12/31/11		(Loss)		at 12/31/2012		(Loss)		at 12/31/2013		(Loss)		6/30/14
	January 1, 2009 adoption	$	479,910	$	-390,368	$	870,278	$	868,772	$	1,506	$	-88,290	$	89,796	$	-21,856	$	111,652	$	100,053	$	11,599	$	11,469	$	130
	Warrants issued in quarter ended 6/30/2009		169,854		20,847		149,007		147,403		1,604		-4,689		6,293		6,293		-		-		-		-		-
	Warrants issued in quarter ended 9/30/2009		39,743		-738		40,481		40,419		62		-1,562		1,624		910		714		714		-		-		-
	Warrants issued in quarter ended 12/31/2009		12,698		617		12,081		12,053		28		-724		752		415		337		337		-		-		-
	Subtotal		702,205				1,071,847
	Warrants issued in quarter ended 3/31/2010		25,553						25,014		539		-5,570		6,109		3,701		2,408		2,408		-		-		-
	Warrants issued in quarter ended 6/30/2010		31,332						30,740		592		-6,122		6,714		6,083		631		631		-		-		-
	Warrants issued in quarter ended 9/30/2010		31,506						20,891		10,615		-44,160		54,775		1,338		53,437		53,437		-		-		-
	Total	$	790,596	$	-369,642	$	1,071,847	$	1,145,292	$	14,946	$	-151,117	$	166,063	$	-3,116	$	169,179	$	157,580	$	11,599	$	11,469	$	130

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policy [Line Items]	'	'
Finished goods	$88,285	$56,818
Raw materials	230,092	18,603
Work-In-Process	42,286	46,754
Total	$360,663	$122,175

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policy [Line Items]	'	'
Total	$247,396	$175,019
Less: Accumulated depreciation	42,738	16,909
Total Fixed Assets, Net	204,658	158,110
Computers and office equipment [Member]	'	'
Summary Of Significant Accounting Policy [Line Items]	'	'
Total	126,234	61,505
Leasehold Improvements [Member]	'	'
Summary Of Significant Accounting Policy [Line Items]	'	'
Total	23,874	23,614
Manufacturing Tooling [Member]	'	'
Summary Of Significant Accounting Policy [Line Items]	'	'
Total	$97,288	$89,900

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

146 Months Ended

6 Months Ended

1 Months Ended

146 Months Ended

1 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Feb. 28, 2014

Jun. 30, 2014

Jul. 31, 2014

Jul. 31, 2014

Computers and office equipment [Member]

Computers and office equipment [Member]

Leasehold Improvements [Member]

Manufacturing Tooling [Member]

Manufacturing Tooling [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

SOK Partners, LLC, [Member]

Investor [Member]

Summary Of Significant Accounting Policy [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders' Equity, Period Increase (Decrease)

'

'

'

'

'

$9,104,000

'

'

'

'

'

'

'

'

'

Debt Instrument, Increase (Decrease) for Period, Net

'

'

'

'

'

4,060,000

'

'

'

'

'

'

'

'

'

Research and Development Expense

131,285

75,264

249,636

133,541

'

'

'

'

'

'

'

'

'

'

'

Amortization of Intangible Assets

'

'

'

'

140,588

'

'

'

'

'

'

'

'

'

'

Property, Plant and Equipment, Useful Life

'

'

'

'

'

'

'3 years

'7 years

'5 years

'3 years

'7 years

'

'

'

'

Stock Issued During Period, Value, New Issues

'

'

'

'

'

'

'

'

'

'

'

2,055,000

2,055,000

'

'

Advertising Expense

$1,250

$0

$7,793

$0

'

'

'

'

'

'

'

'

'

'

'

Securities Purchase Agreement Terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'(i) a senior convertible note, in an original principal amount of $122,196 (the SOK Note), which SOK Note shall be convertible into a certain amount of shares (the SOK Conversion Shares) of Common Stock, in accordance with the terms of the SOK Note, and (ii) a warrant (the SOK Warrant) to initially acquire up to 407,318 additional shares of Common Stock (the SOK Warrant Shares, and collectively with the SOK Note, the SOK Warrant and the SOK Conversion Shares, the SOK Securities). The aggregate purchase price was $100,000 (an approximately 22.2% original issue discount) (the SOK Convertible Notes Offering).

'(i) a senior convertible note, in an original principal amount of $610,978 (the Investor Note), which Investor Note shall be convertible into a certain amount of shares (the Investor Conversion Shares) of the Companys common stock, par value $0.01 (the Common Stock), in accordance with the terms of the Investor Note, and (ii) a warrant (the Investor Warrant) to initially acquire up to 2,036,593 additional shares of Common Stock (the Investor Warrant Shares, and collectively with the Investor Note, the Investor Warrant and the Investor Conversion Shares, the Investor Securities).The aggregate purchase price was $500,000 (an approximately 22.2% original issue discount) (the Investor Convertible Notes Offering).

DEVELOPMENT_STAGE_OPERATIONS_D

DEVELOPMENT STAGE OPERATIONS (Details Textual) (USD $)	147 Months Ended
	Aug. 04, 2014
Development stage operation [Line Items]	'
Common Stock, Shares, Issued	222,975,766
Equity Issuance Per Share Amount	$1.67

STOCKHOLDERS_DEFICIT_STOCK_OPT2

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Details) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Outstanding Number Of Shares	28,929,398	12,663,566
Issued - Number of Shares	5,115,061	17,986,157
Expired - Number of Shares	-495,768	-1,159,995
Exercised - Number of shares	-345,187	-560,330
Outstanding Number Of Shares	33,203,504	28,929,398
Outstanding - Average Exercise Price	$0.09	$0.09
Issued - Average Exercise Price	$0.11	$0.09
Expired - Average Exercise Price	$0.34	$0.24
Exercised - Average Exercise Price	$0.02	$0.01
Outstanding - Average Exercise Price	$0.10	$0.09
Warrant [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Outstanding Number Of Shares	34,643,829	35,132,136
Issued - Number of Shares	2,133,812	25,739,682
Expired - Number of Shares	-4,171,733	-8,326,862
Exercised - Number of shares	-2,220,831	-17,901,127
Outstanding Number Of Shares	30,385,077	34,643,829
Outstanding - Average Exercise Price	$0.14	$0.13
Issued - Average Exercise Price	$0.27	$0.12
Expired - Average Exercise Price	$0.16	$0.18
Exercised - Average Exercise Price	$0.13	$0.11
Outstanding - Average Exercise Price	$0.15	$0.14

STOCKHOLDERS_DEFICIT_STOCK_OPT3

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Details 1) (USD $)

12 Months Ended

6 Months Ended

6 Months Ended

Dec. 31, 2009

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Stock Options One [Member]

Stock Options Two [Member]

Stock Options Three [Member]

Stock Options Four [Member]

Stock Options Five [Member]

Stock Options Six [Member]

Stock Options Seven [Member]

Stock Options Eight [Member]

Stock Options Nine [Member]

Stock Options Ten [Member]

Stock Options Eleven [Member]

Stock Options Twelve [Member]

Stock Options Thirteen [Member]

Stock Options Fourteen [Member]

Stock Options Fifteen [Member]

Stock Options Sixteen [Member]

Stock Options Seventeen [Member]

Stock Options Eighteen [Member]

Stock Options Nineteen [Member]

Stock Options Twenty [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Warrant One [Member]

Warrant Two [Member]

Warrant Three [Member]

Warrant Five [Member]

Warrant Six [Member]

Warrant Seven [Member]

Warrant Eight [Member]

Warrant Nine [Member]

Warrant Ten [Member]

Warrant Eleven [Member]

Warrant Twelve [Member]

Warrant Thirteen [Member]

Warrant Fourteen [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Range of Exercise Prices

'

$0.01

$0.07

$0.07

$0.08

$0.08

$0.08

$0.09

$0.13

$0.14

$0.15

$0.17

$0.19

$0.20

$0.23

$0.25

$0.27

$0.29

$0.32

$0.33

$0.34

$0.10

$0.09

$0.09

$0.01

$0.08

$0.08

$0.12

$0.15

$0.17

$0.18

$0.20

$0.20

$0.25

$0.27

$0.33

$0.77

$0.15

$0.14

$0.13

Shares

'

550,000

10,000

177,286

14,400,000

1,740,508

9,300,000

400,000

226,415

242,857

1,110,000

755,000

162,162

250,000

3,019,565

250,000

370,373

100,000

94,338

25,000

20,000

33,203,504

28,929,398

12,663,566

30,000

2,083,333

7,714,286

200,000

15,314,951

407,318

333,333

1,770,833

87,500

375,000

111,111

1,615,383

342,029

30,385,077

34,643,829

35,132,136

Weighted Average Remaining Life

'2 years 6 months

'7 years 7 days

'8 years 8 months 12 days

'9 years 1 month 13 days

'8 years 8 months 16 days

'8 years 8 months 19 days

'8 years 1 month 17 days

'7 years 6 months 25 days

'9 years 14 days

'9 years 14 days

'7 years 11 months 19 days

'9 years 9 months 14 days

'9 years 9 months 4 days

'9 years 8 months 19 days

'9 years 8 months 8 days

'9 years 7 months 24 days

'9 years 6 months 4 days

'9 years 3 months 11 days

'9 years 3 months 4 days

'9 years 2 months 26 days

'9 years 3 months

'

'

'

'1 year 5 months 8 days

'25 days

'3 years 8 months 16 days

'3 years 6 months 29 days

'3 years 6 months 7 days

'1 year 4 months 17 days

'3 years 11 months 19 days

'3 years 11 months 1 day

'7 months 6 days

'3 months 7 days

'3 years 2 months 16 days

'4 years 9 months 4 days

'4 days

'

'

'

STOCKHOLDERS_DEFICIT_STOCK_OPT4

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Details 2) (USD $)

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

6 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

6 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2008

Jun. 30, 2014

Dec. 31, 2010

Jun. 30, 2014

Dec. 31, 2011

Jun. 30, 2014

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2010

Jun. 30, 2014

Dec. 31, 2011

Jun. 30, 2014

Dec. 31, 2012

Jun. 30, 2014

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Minimum [Member]

Maximum [Member]

Warrant One [Member]

Warrant One [Member]

Warrant Two [Member]

Warrant Two [Member]

Warrant Three [Member]

Warrant Three [Member]

Warrant Three [Member]

Warrant Three [Member]

Warrant Four [Member]

Warrant Four [Member]

Warrant Four [Member]

Warrant Five [Member]

Warrant Five [Member]

Warrant Five [Member]

Warrant Five [Member]

Warrant Six [Member]

Warrant Six [Member]

Warrant Six [Member]

Warrant Seven [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Stock Options One [Member]

Stock Options One [Member]

Stock Options Two [Member]

Stock Options Two [Member]

Stock Options Three [Member]

Stock Options Three [Member]

Stock Options Three [Member]

Stock Options Three [Member]

Stock Options Four [Member]

Stock Options Four [Member]

Stock Options Four [Member]

Stock Options Four [Member]

Stock Options Five [Member]

Stock Options Five [Member]

Stock Options Five [Member]

Stock Options Six [Member]

Stock Options Seven [Member]

Stock Options Seven [Member]

Stock Options Seven [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Stock Options [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issued - Number of Shares

'

'

342,029

'

30,000

'

2,458,333

'

'

'

5,352,451

'

'

20,068,452

'

'

'

2,133,812

'

'

'

2,133,812

25,739,682

'

'

'

410,000

'

550,000

'

9,477,286

'

'

'

17,901,157

'

'

'

4,865,061

'

'

'

'

'

'

5,115,061

17,986,157

'

'

Shares

'

'

'

30,000

'

2,083,333

'

7,714,286

'

'

'

'

'

'

200,000

'

'

15,314,951

'

'

407,318

30,385,077

34,643,829

35,132,136

'

'

'

550,000

'

10,000

'

177,286

'

'

'

14,400,000

'

'

1,740,508

'

'

9,300,000

400,000

'

'

33,203,504

28,929,398

12,663,566

'

Issued - Average Exercise Price

$0.12

$0.24

$0.77

'

$0.01

'

'

'

$0.08

$0.25

'

$0.15

$0.20

'

'

$0.08

$0.20

'

$0.17

$0.33

'

$0.27

$0.12

'

$0.01

$0.77

$0.15

'

$0.01

'

'

'

$0.07

$0.08

'

'

$0.07

$0.34

'

$0.15

$0.25

'

'

$0.19

$0.25

$0.11

$0.09

'

$0.01

STOCKHOLDERS_DEFICIT_STOCK_OPT5

STOCKHOLDERS' DEFICIT, STOCK OPTIONS AND WARRANTS (Details Textual) (USD $)

1 Months Ended

2 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

2 Months Ended

2 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

146 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

2 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

Mar. 31, 2014

Feb. 28, 2014

31-May-13

Apr. 30, 2013

Jan. 31, 2013

Nov. 30, 2012

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2014

Jun. 30, 2014

Jun. 30, 2013

Mar. 31, 2014

Dec. 31, 2009

Aug. 04, 2014

Dec. 31, 2013

Oct. 31, 2013

Sep. 11, 2013

Jan. 15, 2013

Mar. 28, 2012

Sep. 07, 2011

Jun. 22, 2010

Jun. 30, 2014

Feb. 28, 2014

Jan. 31, 2014

Apr. 30, 2013

Jun. 30, 2014

Jan. 31, 2013

Jun. 30, 2013

Mar. 31, 2013

Mar. 15, 2013

Jun. 30, 2013

Apr. 30, 2013

Jan. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Mar. 15, 2013

Mar. 31, 2013

Mar. 15, 2013

Feb. 28, 2014

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Sep. 30, 2013

Oct. 31, 2013

Sep. 10, 2013

Apr. 15, 2013

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Sep. 30, 2013

Sep. 10, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Sep. 30, 2013

Sep. 10, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

SOK Partners, LLC, [Member]

Dr.Samuel Herschowitz [Member]

CEO [Member]

CEO [Member]

CEO [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement 2 [Member]

Consultant [Member]

Consultant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Warrant Holder [Member]

Warrant Holder [Member]

Preferred Holder [Member]

Preferred Holder [Member]

Twenty Four Warrant Holders [Member]

One Warrant Holder [Member]

Stock Incentive Plan 2012 [Member]

Stock Incentive Plan 2012 [Member]

Stock Options and Warrants [Member]

Stock Options and Warrants One [Member]

Stock Options and Warrants Two [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

SOK Partners, LLC, [Member]

Private Placement [Member]

Private Placement [Member]

Private Placement 2 [Member]

Warrant [Member]

Stock Options and Warrants [Member]

Stock Options and Warrants [Member]

Warrant [Member]

Stock Options and Warrants [Member]

Stock Options and Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted Average Remaining Life

'

'

'

'

'

'

'

'

'

'

'

'

'2 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'10 years

'2 years

'

'

'

'

'5 years

'

'6 years 6 months

'

'

'

'

'10 years

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

59.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

66.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issued - Average Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.27

$0.12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.12

'

'

$0.01

$0.06

'

'

$0.24

'

'

$0.77

$0.18

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Volatility Description

'

'

'

'

'

'

'

'

'

'The Company compiled historical volatilities over a period of 2 to 7 years of 15 small-cap medical companies traded on major exchanges and 10 mid-range medical companies on the OTC Bulletin Board and combined the results using a weighted average approach.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of debt discount

'

'

'

'

'

'

'

$275,640

'

$0

$92,538

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument Convertible Remaining Discount Amortization Period 1

'

'

'

'

'12 months

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

1.37%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.44%

0.78%

'

'

'

'

'

2.75%

2.04%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

'

'

'

'

'

'

'

'

'

59.00%

'

'

63.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

59.00%

66.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31,341,741

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price

'

'

'

'

'

'

'

'

'

$0.10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Weighted Average Remaining Contractual Term 1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'8 years 9 months 14 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Expense

'

'

'

'

'

'

'

'

'

'

1,378,541

'

'

'

'

'

'

'

'

'

'

352,762

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized, Stock Options

'

'

'

'

'

'

'

'

'

259,398

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1

'

'

'

'

'

'

'

'

'

'18 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized

'

'

'

'

'

'

'

'

'

800,000,000

'

'

'

'

800,000,000

'

'

300,000,000

'

200,000,000

80,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000,000

50,000,000

'

'

'

'

'

'

300,000,000

'

'

'

'

'

'

800,000,000

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

156,243

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Notes Converted Into Common Stock

'

'

1,116,084

'

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500,000

6,000,000

'

'

4,611,111

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price

'

'

'

$0.10

$0.12

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

$0.07

'

'

'

'

'

'

'

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accumulated discounts on current portion of convertible debt (in dollars)

'

'

'

'

77,644

'

'

'

'

46,072

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

23,876

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Effective Interest Rate

'

'

'

'

'

'

'

'

'

24.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Grants Increase For Threshold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued under PPM to five investors at $.07 per share (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,571,429

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value (in dollars per share)

'

'

$0.01

'

'

'

'

'

'

$0.01

'

'

'

'

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued, Price Per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.07

$0.07

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

$0.33

$0.10

'

'

'

$0.10

$0.18

'

$0.33

$0.18

'

'

'

'

$0.25

'

'

'

'

'

'

$0.27

'

'

'

'

'

'

'

$0.20

'

'

'

'

$0.17

$0.08

$0.15

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.15

'

'

'

'

'

'

$0.46

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

1,600,000

'

'

'

'

'

444,444

'

1,615,383

444,444

'

'

4,615,385

'

'

'

'

'

'

'

'

111,111

'

'

'

'

'

7,142,857

7,142,858

'

'

'

'

'

407,318

7,142,858

7,142,857

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Payable

'

'

'

'

'

11,169

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

500,000

'

2,055,000

2,055,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

'

'

357,163

1,041,622

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,550

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.02

$0.01

$0.15

'

'

'

'

'

$0.01

'

$0.13

$0.11

'

'

'

'

'

'

'

'

'

'

'

$0.13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Stock Options Exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,044,490

$125,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of net exercise provision shares

'

'

'

'

'

'

6,533,788

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock Conversion Price, Per Share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.26

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Expiration

'

'

'

'

'

'

'

'

'

'five years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Of Additional Warrants Issued To Purchase Common Stock

'

30.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Terms of Conversion

'

'

'

'

'

'

'

'

'

'Preferred Shares are convertible at the option of the holder into the number of shares of Common Stock determined by dividing the stated value of the Preferred Shares being converted by the conversion price of $0.26, subject to adjustment for stock splits, reverse stock splits and similar recapitalization events. If the Company issues additional shares of Common Stock, other than certain stock that is excluded under the terms of the Securities Purchase Agreement, in one or more capital raising transactions with an aggregate purchase price of at least $100,000 for a price less than the then existing conversion price for the Preferred Shares (the New Issuance Price), then the then existing conversion price shall be reduced to the New Issuance Price, provided, however, that under no circumstances shall the New Issuance Price be less than $0.13 or reduced to a price level that would be in breach of the listing rules of any stock exchange

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beneficial Ownership Limitation, Percentage

'

'

'

'

'

'

'

'

'

4.99%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Shareholders, Receivable, Upon Any Liquidation, Description

'

'

'

'

'

'

'

'

'

'an amount equal to $2,055,000 times 1.2, plus all declared but unpaid dividends

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless Exercise Of Common Stock Warrants Total

'

'

'

'

'

'

'

'

1,158,131

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Conversion of Convertible Securities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

116,934

72,760

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless Exercise Of Common Stock Shares Issued

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion Of Stock Price Per Share

'

'

'

'

'

'

'

'

'

$0.26

'

$0.26

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Dividend Rate, Percentage

6.00%

'

'

'

'

'

'

'

'

6.00%

'

6.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

325,187

333,330

'

'

'

'

'

'

200,000

200,000

2,220,831

17,901,127

'

'

'

'

'

'

333,334

279,366

'

'

10,444,898

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

LOSS_PER_SHARE_Details

LOSS PER SHARE (Details) (USD $)	3 Months Ended					6 Months Ended
	Jun. 30, 2014		Jun. 30, 2013		Mar. 31, 2013	Jun. 30, 2014		Jun. 30, 2013
Numerator:	'		'		'	'		'
Net loss available in basic and diluted calculation	($1,735,954)		($1,175,535)		'	($3,352,949)		($3,277,061)
Denominator:	'		'		'	'		'
Weighted average common shares outstanding-basic	222,620,910		121,267,500		'	221,922,352		111,045,552
Effect of diluted stock options and warrants	0	[1]	0	[1]	'	0	[1]	0	[1]
Weighted average common shares outstanding-basic (in shares)	222,620,910		121,267,500		'	221,922,352		111,045,552
Loss per common share-basic and diluted (in dollar per share)	($0.01)		($0.01)		($0.01)	($0.02)		($0.03)
[1]	The number of shares underlying options and warrants outstanding as of June 30, 2014 and June 30, 2013 are 63,588,581 and 84,320,276 respectively. The effect of the shares that would be issued upon exercise of such options and warrants has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

LOSS_PER_SHARE_Details_Textual

LOSS PER SHARE (Details Textual) (USD $)	Jun. 30, 2014	Jun. 30, 2013
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]	'	'
Options and Warrants Outstanding	$63,588,581	$84,320,276

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Deferred Tax Asset:	'	'
Net Operating Loss	$7,920,000	$3,259,000
Other	648,000	59,000
Total Deferred Tax Asset	8,568,000	3,318,000
Less Valuation Allowance	8,568,000	3,318,000
Net Deferred Income Taxes	$0	$0

INCOME_TAXES_Details_Textual

INCOME TAXES (Details Textual) (USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014
Tax Credit Carryforward [Line Items]	'
Valuation Allowance Percentage	100.00%
Operating Loss Carryforwards, Expiration Date	31-Dec-22
Domestic Tax Authority [Member]	'
Tax Credit Carryforward [Line Items]	'
Operating Loss Carryforwards	16
Operating Loss Carryforwards, Valuation Allowance	7.1
Operating Loss Carryforwards, Expiration Period	'beginning in 2022
State and Local Jurisdiction [Member]	'
Tax Credit Carryforward [Line Items]	'
Operating Loss Carryforwards	17.1
Operating Loss Carryforwards, Valuation Allowance	1.5
Operating Loss Carryforwards, Expiration Period	'2022 through 2034

RENT_OBLIGATION_Details

RENT OBLIGATION (Details) (USD $)	Jun. 30, 2014
Operating Leased Assets [Line Items]	'
2015	$37,000
2016	38,000
2017	39,000
2018	3,600
2019	$0

RENT_OBLIGATION_Details_Textua

RENT OBLIGATION (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Property Subject to or Available for Operating Lease [Line Items]	'	'	'	'
Operating Leases, Rent Expense	$15,447	$15,173	$33,056	$35,159
Lease Expiration Date	'	'	31-Jan-18	'
Lessee Leasing Arrangements, Operating Leases, Term of Contract	'	'	'5 years	'

LIABILITY_FOR_EQUITYLINKED_FIN2

LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS (Details) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock price	'	$0.35
Exercise price	'	$0.46
Expected life	'	'2 years 6 months
Expected volatility	59.00%	63.00%
Assumed dividend rate	0.00%	'
Risk-free interest rate - Minimum	0.13%	'
Risk-free interest rate - Maximum	2.97%	'
Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock price	0.06	'
Exercise price	0.01	'
Expected life	'2 years	'
Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock price	0.5	'
Exercise price	0.325	'
Expected life	'6 years 6 months	'

LIABILITY_FOR_EQUITYLINKED_FIN3

LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS (Details 1) (USD $)	3 Months Ended						9 Months Ended	12 Months Ended
	Sep. 30, 2010	Jun. 30, 2010	Mar. 31, 2010	Dec. 31, 2009	Sep. 30, 2009	Jun. 30, 2009	Sep. 30, 2010	Dec. 31, 2009	Dec. 31, 2008
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Initial Value	$31,506	$31,332	$25,553	$12,698	$39,743	$169,854	'	$702,205	$479,910
Annual Gain (Loss)	'	'	'	617	-738	20,847	-369,642	'	-390,368
Total	'	'	'	'	'	'	790,596	'	'
Value At 2009 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Initial Value	'	'	'	12,081	40,481	149,007	'	1,071,847	870,278
Total	'	'	'	'	'	'	1,071,847	'	'
Value At 2010 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Initial Value	10,615	592	539	28	62	1,604	'	'	1,506
Total	'	'	'	'	'	'	14,946	'	'
Gain Loss 2010 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Annual Gain (Loss)	20,891	30,740	25,014	12,053	40,419	147,403	'	'	868,772
Total	'	'	'	'	'	'	1,145,292	'	'
Value At 2011 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Initial Value	54,775	6,714	6,109	752	1,624	6,293	'	'	89,796
Total	'	'	'	'	'	'	166,063	'	'
Gain Loss 2011 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Annual Gain (Loss)	-44,160	-6,122	-5,570	-724	-1,562	-4,689	'	'	-88,290
Total	'	'	'	'	'	'	-151,117	'	'
Value At 2012 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Initial Value	53,437	631	2,408	337	714	0	'	'	111,652
Total	'	'	'	'	'	'	169,179	'	'
Gain Loss 2012 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Annual Gain (Loss)	1,338	6,083	3,701	415	910	6,293	'	'	-21,856
Total	'	'	'	'	'	'	-3,116	'	'
Value At 2013 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Initial Value	0	0	0	0	0	0	'	'	11,599
Total	'	'	'	'	'	'	11,599	'	'
Gain Loss 2013 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Annual Gain (Loss)	53,437	631	2,408	337	714	0	'	'	100,053
Total	'	'	'	'	'	'	157,580	'	'
Value at 2014 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Total	0	0	0	0	0	0	130	'	130
Gain Loss 2014 [Member]	'	'	'	'	'	'	'	'	'
Class of Warrant or Right [Line Items]	'	'	'	'	'	'	'	'	'
Annual Gain (Loss)	$0	$0	$0	$0	$0	$0	$11,469	'	$11,469

LIABILITY_FOR_EQUITYLINKED_FIN4

LIABILITY FOR EQUITY-LINKED FINANCIAL INSTRUMENTS (Details Textual) (USD $)	6 Months Ended	12 Months Ended			6 Months Ended	12 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2009	Dec. 31, 2013	Jan. 02, 2009	Jun. 30, 2014	Dec. 31, 2010	Jun. 30, 2014	Dec. 31, 2010
					Minimum [Member]	Minimum [Member]	Maximum [Member]	Maximum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]	'	'	'	'	'	'	'	'
Warrants Not Settleable In Cash, Fair Value Disclosure	'	'	'	$479,910	'	'	'	'
Weighted Average Remaining Life	'	'2 years 6 months	'	'	'2 years	'	'6 years 6 months	'
Reduction In Stock Price	'	'	'	'	'	$0.22	'	$0.50
Additional Paid in Capital	'	'	'	486,564	'	'	'	'
Retained Earnings (Accumulated Deficit)	'	'	'	6,654	'	'	'	'
Total Current Liabilities	$3,905,940	'	$3,469,065	$479,910	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	59.00%	63.00%	'	'	'	'	'	'
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price	'	$0.46	'	'	$0.01	'	$0.33	'
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Stock Price	'	$0.35	'	'	$0.06	'	$0.50	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	'	1.37%	'	'	'	'	'	'

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Textual) (USD $)

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

31-May-13

Apr. 30, 2013

Nov. 30, 2012

Aug. 31, 2012

Jun. 30, 2012

Apr. 30, 2012

Mar. 31, 2012

Sep. 30, 2013

Jun. 30, 2014

Dec. 31, 2012

Aug. 04, 2014

Feb. 28, 2014

Sep. 11, 2013

Jun. 30, 2013

Jan. 31, 2013

Mar. 28, 2012

Dec. 31, 2008

Jun. 30, 2013

Jun. 30, 2013

Mar. 28, 2012

Mar. 28, 2012

Dec. 31, 2008

Sep. 11, 2013

Aug. 31, 2012

Apr. 30, 2012

Dec. 31, 2013

Apr. 30, 2012

Aug. 15, 2012

Apr. 30, 2012

Aug. 15, 2012

Sep. 11, 2013

31-May-12

Mar. 31, 2012

Dec. 31, 2012

Jan. 31, 2014

Dec. 31, 2013

Jun. 30, 2014

Jan. 31, 2014

Feb. 28, 2014

Mar. 31, 2012

Mar. 31, 2012

Mar. 14, 2012

Mar. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Jul. 31, 2014

Jun. 30, 2012

Jun. 30, 2012

Feb. 28, 2014

Feb. 04, 2014

Minimum [Member]

Maximum [Member]

First Advance [Member]

Second Advance [Member]

Related Party [Member]

Samuel Herschkowitz [Member]

Samuel Herschkowitz [Member]

Samuel Herschkowitz [Member]

Samuel Herschkowitz [Member]

Samuel Herschkowitz [Member]

Samuel Herschkowitz [Member]

Samuel Herschkowitz [Member]

Samuel Herschkowitz [Member]

Sok Partners [Member]

Sok Partners [Member]

Sok Partners [Member]

Sok Partners [Member]

Sok Partners [Member]

Sok Partners [Member]

Sok Partners [Member]

Sok Partners [Member]

Sok Partners [Member]

Sok Partners [Member]

Sok Partners [Member]

Sok Partners [Member]

Dr Herschkowitz and Sok Partners Llc [Member]

Gadbaw [Member]

Morawetz [Member]

SOK Partners, LLC, [Member]

Board of Directors Chairman [Member]

Director [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Non-Convertible Grid Note [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Non-Convertible Grid Note [Member]

Non-Convertible Grid Note [Member]

Non-Convertible Grid Note [Member]

Non-Convertible Grid Note [Member]

Non-Convertible Grid Note [Member]

Minimum [Member]

Maximum [Member]

Common Stock [Member]

Subsequent Event [Member]

Preferred Stock [Member]

Common Stock [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments Made To Officers One

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$25,000

'

'

'

Proceeds from Issuance or Sale of Equity

'

'

'

'

'

'

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments Made To Officers Two

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30,000

'

'

Related Party Transaction, Due from (to) Related Party

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000

'

'

'

'

46,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Converible Note Percentage

'

'

20.00%

20.00%

'

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Converible Note Principal Amount

'

'

156,243

600,000

'

'

240,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes Payable, Total

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

357,282

'

'

'

'

305,589.04

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Effective Interest Rate

'

'

'

'

'

'

'

'

24.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Advance Under Note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

84,657

'

'

'

'

'

'

'

'

'

'

300,000

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash Advance Net Of Interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price

'

$0.10

'

'

'

'

'

'

'

'

'

'

$0.01

'

$0.12

$0.07

'

'

'

'

'

'

'

'

'

'

'

$0.01

'

$0.07

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Conversion of Units

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,615,385

4,615,385

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Conversion of Units

'

'

'

'

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Other

'

'

'

'

'

'

1,546,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Transferred During Period

'

'

'

'

'

7,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued Related Party Transactions One

'

'

'

'

277,778

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Price Per Share Related Party Transactions

'

'

'

'

$0.09

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation Issued In Lieu Of Cash

'

'

'

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Shares Related Party Transactions

'

'

'

'

30,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants Price Per Share Related Party Transactions

'

'

'

'

$0.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued Related Party Transactions Two

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

26,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Issued Related Party Transactions Three

'

'

1,562,430

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Related Party Debt

'

'

155,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Note Due Date

'

31-Aug-13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Related Party Transaction, Description of Transaction

'

'

'

'

'

'

'

'

'(i) financing raising not less than $1 million, compensation of $75,000; (ii) a going private transaction, compensation of $200,000 or greater and (iii) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $3,000,000. In May 2013 Dr. Herschkowitz received $75,000 after the Company surpassed raising $1 million.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Equity Bonus Valued At Common Stock Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.01

$0.07

'

'

'

'

'

'

'

'

'

Additional Issue Of Common Stock Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

16,000,000

'

'

'

'

'

'

'

'

Stock Issued During Period Shares New Issues

357,163

1,041,622

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,500,000

'

'

'

'

'

'

'

13,250,000

'

'

'

'

'

'

'

'

'

13,250,000

'

'

'

'

'

25,000

'

Percentage Of Interest Rate On Event Of Default

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

24.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Of Accrued Interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds From Offering Of Securities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

4,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation Payment Pursuant To Merger

'

'

'

'

'

'

'

'

'listing the Companys shares on NASDAQ pursuant to an underwritten offering of the Companys securities resulting in gross proceeds of between $5 million and $30 million, then the Company would have to be required to deliver to Dr. Herschkowitz the following compensation: (A) $75,000 upon consummating the shell merger, (B) $150,000 upon consummating the qualifying financing round and (C) 3% of the gross proceeds of the NASDAQ underwriting, which payment shall under no circumstances be less than $200,000 or greater than $1,000,000. The Company was also required to reimburse Dr. Herschkowitz at his actual out-of-pocket cost for reasonable expenses incurred in connection with the shell transactions, with a maximum limit of $10,000 for such expenses.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Shares received on resignation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

50,000

'

'

'

'

'

Common shares received per share on resignation

'

'

'

'

'

'

'

$0.33

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Compensation received from serving as board members

'

'

'

'

'

'

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of shares to satisy previous contractual agreements

'

'

'

'

'

'

'

30,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Periodic Payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

314,484

'

'

'

'

'

'

'

680,444

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Stock, Shares Converted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

22,463,172

'

'

'

'

'

'

'

48,603,721

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Notes Payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20,000

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Maturity Date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28-Feb-14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Effective Percentage

'

'

'

'

'

'

'

'

24.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Of Gross Proceeds Received In Advance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount Received In Three Tranches

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage Of Increase In Interest In Case Of Default

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, New Issues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$19,231

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

'

'

'

'

1,615,383

'

4,615,385

1,600,000

'

444,444

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,846

Securities Purchase Agreement Terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'(i) a senior convertible note, in an original principal amount of $122,195.60 (the SOK Note), which SOK Note shall be convertible into a certain amount of shares (the SOK Conversion Shares) of Common Stock, in accordance with the terms of the SOK Note, and (ii) a warrant (the SOK Warrant) to initially acquire up to 407,318 additional shares of Common Stock (the SOK Warrant Shares, and collectively with the SOK Note, the SOK Warrant and the SOK Conversion Shares, the SOK Securities) for an aggregate purchase price of $100,000 (an approximately 22.2% original issue discount) (the SOK Convertible Notes Offering).

'

'

'

'

Retirement_Savings_Plan_Detail

Retirement Savings Plan (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]	'	'	'	'
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	'	'	100.00%	'
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	'	'	4.00%	'
Defined Contribution Plan, Employer Discretionary Contribution Amount	$8,171	$12,304	$15,494	$18,097

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (USD $)	6 Months Ended
	Jun. 30, 2014
Litigation Settlement, Amount	$500,000
Estimated Litigation Liability, Current	$200,000
Loss Contingency, Settlement Agreement, Terms	'Payment of the outstanding balance under the Settlement Agreement will be accelerated if the Company raises $2 million or more of gross dollars in a single funding round or raises aggregate funding of $4 million of gross dollars on or before April 10, 2015.

Supplemental_Cash_Flow_Data_De

Supplemental Cash Flow Data (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Schedule Of Cash Flow Supplemental Disclosures [Line Items]	'	'	'	'
Interest Paid, Total	$3,468	$15,522	$21,606	$41,930